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Abstract 
 
‘Investigating the Regulation of Growth by Nitric Oxide Signalling in 
Drosophila melanogaster’ 
A thesis submitted to the University of Sussex for the Degree of Master of Philosophy 
By Mona Khosravi 
School of Life Sciences 
September 2011 
 
Mechanisms associated with growth regulation have been shown to be highly conserved 
in mammals and Drosophila, especially when examining the insulin signalling pathway. 
Previous studies suggest that nitric oxide (NO) signalling can inhibit growth and cell 
proliferation in a Drosophila forkhead box O (dFOXO)- dependent manner. dFOXO is 
a component of the insulin signalling pathway and has also been demonstrated to inhibit 
growth via its interactions with components in this pathway; however, the mechanism 
by which dFOXO and NO interact is unclear. 
Since inhibition of growth by NO is dependent on dFOXO, this thesis examines the 
effect of co-expressing nitric oxide synthase II (NOS2) with three dFOXO alleles 
(dFOXO
25
, dFOXO
21
 and dFOXO
BG01018
) in Drosophila salivary glands taken from third 
instar larvae. It concludes that the dFOXO
25
 null allele appeared to be the strongest 
deletion of dFOXO given that salivary gland nuclei appear most similar in size to the 
wild type. This indicates that NO-induced growth inhibition only occurred to a very 
small degree as a result of a powerful loss-of-function of dFOXO exhibited in dFOXO
25
 
homozygotes. 
This thesis also investigates the effects of NO on salivary glands taken from the same 
developmental stage when co-expressed with overexpressed oncogenes, dMyc and 
Ras
V12
. Nuclei measurements were larger than the NOS2-only expressing line and 
smaller than the lines expressing only each of the oncogenes. However, TEM analysis 
revealed that co-expression might induce endoplasmic reticulum (ER) stress in the 
glands. Research shows that NO and these oncogenes can provide the reactants 
necessary to generate peroxynitrite, which is associated with the generation of ER 
stress.  
When examining the effects of these growth regulators on mitochondria and Golgi, this 
thesis reports that dFOXO, NOS2 and dMyc can increase mitochondrial biogenesis. 
Golgi was unaffected by expression of the growth regulators
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Chapter 1 
 
General Introduction 
 
1.1. Nitric Oxide 
 
NO acts as a diffusible, intercellular messenger in signalling pathways and is highly 
reactive with a biological half-life of less than a second in vivo (Pacher et al., 2007). NO 
has crucial roles in immunity, the nervous system and vasodilation; however, it can also 
lead to pathophysiology when present at inappropriate levels in certain tissues.  
This chapter will briefly outline various signalling mechanisms of NO in different organ 
systems and address the effects that these have on growth, metabolism and age-related 
diseases. 
1.1.1 Nitric Oxide Biosynthesis 
The amino acid, L-arginine, reacts with nitric oxide synthases (NOSs) in the process of 
NO biosynthesis (Palmer et al., 1988). This is an oxidative process during which L-
arginine is converted into L-citrulline as illustrated below: 
Fig 1.1. Biosynthesis of NO  
Overall reaction 
L-arginine + 2 NADPH + O2 → L-citrulline + NO + 2NADP
+
 
 
Fig. 1.1 Biosynthesis of NO from L-arginine. (Bruckdorfer, 2005) 
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Therefore, NOS enzymes catalyse the formation of NO and require the following 
obligatory cofactors: calcium-calmodulin, HEME and flavins (Lacza, 2006). NO can 
diffuse from the source of synthesis to a neighbouring cell where it has several 
cytoplasmic targets. Given its short half-life, this range is approximately 100μm 
(Lancaster, 1997) qualifying NO as a short-range signalling molecule; nonetheless, it 
has many diverse targets, modifying the function of a wide range of molecular 
processes. NO can target ribonucleotide reductase, cyclooxygenases and several 
mitochondrial enzymes (Dawson and Dawson, 1995; Garthwaite and Boulton, 1995). 
Nakaya et al. (2000) also showed that NO can regulate cell-cycle proteins, such as p53, 
to induce cell cycle arrest via phosphorylation in signalling pathways. 
1.1.2. NOS isoforms: nNOS, eNOS, iNOS, mtNOS and dNOS 
The three main NOS isoforms in mammals are well documented; they are: neuronal 
NOS (nNOS/NOS1), inducible NOS (iNOS/NOS2) and endothelial NOS (eNOS/NOS3) 
(Knott and Bossy-Wetzel, 2009). Furthermore, Drosophila expresses a variant of the 
NOS gene known as dNOS (Kuzin et al., 1996). More recently, research addresses 
another classification of NOS, mitochondrial NOS (mtNOS) (Ghafourifar and Cadenas, 
2005). Each isoform is located in different tissue types and expressed over different 
periods at varying levels; these distinctions occur as a result of their specific 
physiological roles.  
1.1.3. nNOS 
nNOS acts in neurons specific to both the central and peripheral nervous systems. NO is 
required as a neurotransmitter in the nervous system for neuronal plasticity and 
intercellular communication (Knott and Bossy-Wetzel, 2009). NO biosynthesis is 
relatively low in this system, but is constantly generated by constitutively active nNOS. 
NO acts in several nervous system processes to help coordinate important neural signals 
such as relaxation of the alimentary canal to facilitate digestion and signalling to neural 
blood vessels allowing dilation in penile and cerebral arteries (Bredt et al., 1991; 
Burnett et al., 1992). 
1.1.4. eNOS 
Similarly, NO production via eNOS is comparable as this isoform is also constitutively 
active, producing NO from L-arginine at a low, consistent rate to maintain physiological 
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function (Moncada et al., 2006). However, this biosynthesis takes place in endothelial 
tissue in the vascular system, in which NO acts to relax the surrounding tissue and 
promote vasodilation and vascular smooth muscle cells are common sites of eNOS 
activity.  
eNOS-produced NO can bind with the protoporphyrin ring in the heme group of soluble 
guanylate cyclase (sGC) to generate the second messenger molecule, 3’, 5’-cyclic 
guanosine monophosphate (cGMP) (Bruckdorfer, 2005). As a result, cGMP can then 
interact with phosophodiesterases (Hartzel and Fishmeister, 1986), protein kinases 
(Paupardin-Tritsch et al., 1986), and ion channels (Nawy and Jahr, 1990). These 
pathways have been found to generate signals to the nucleus, modifying gene 
transcription and thus, produce a sustained or permanent change in the cell (Gudi et al., 
1999). In the endothelium NO presents as a relaxation-inducing molecule that regulates 
vascular tone (Ignarro et al., 1987). 
1.1.5. iNOS and macrophage function  
In contrast, iNOS synthesises NO over a relatively shorter period of time and at a higher 
level. This production occurs in the immune system, specifically glia and macrophages, 
upon activation via pathogen recognition (Merrill et al., 1997). NO biosynthesis in this 
system is, therefore, induced and the isoform acts to trigger cell death by toxic levels of 
NO production. Additionally, NO can react with superoxide anions to form the toxic 
oxidant, peroxynitrite, which can destroy pathogens by targeting their nucleic acids, 
proteins and oxidising lipids (Szabó, 2003). 
1.1.6. mtNOS 
The most recently discovered isoform, mtNOS, is thought to produce NO that functions 
to buffer Ca
2+
 and control energy production in the inner membrane of mitochondria 
(Ghafourifar and Cadenas, 2005).  
Lacza et al. (2006) discussed other studies that challenge the existence of mtNOS. Such 
studies argued that a NOS-like sequence is not contained in the mitochondrial genome, 
meaning that NOS has to be imported into the mitochondria, appropriately folded and 
supplied with the obligatory cofactors previously mentioned (Brookes, 2004). Lacza et 
al. (2006) acknowledges these arguments and suggests that eNOS may be mistaken for 
a novel, mtNOS isoform. Additionally, at least three different sources of NO can 
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explain its presence in mitochondria: nitrosothiols acting as NO donors, eNOS 
attachment to the outer mitochondrial membrane and nitrate reductase activity 
demonstrated in the electron transport chain. Yet, investigating synthesis of NO in 
mitochondria is problematic. Mitochondria act as NO-sinks, making it difficult to 
measure intramitochondrial levels of NO even if it is produced there (Pearce et al., 
2002). Furthermore, when preparing mitochondria for analysis, contamination is always 
present between 1-4% and may influence results if contaminants contain 
extramitochondrial NOS (Sims, 1990). 
Nevertheless, several studies confirm the existence of mtNOS (or at least eNOS in 
mitochondria) and characterise its function as being essential for mitochondrial 
biogenesis via eNOS null mutations (Nisoli et al., 2003). 
1.1.7. dNOS 
Recently, Drosophila has been demonstrated to express a solitary NOS enzyme (dNOS) 
which has functions in pathways corresponding to development, immunity and 
behaviour (Kuzin et al., 1996; Wingrove and O’Farrell, 1999; Gibbs, 2003). Regulski 
and Tully (1995) first characterised dNOS by cloning the gene and screening the 
Drosophila genome with a phage library utilising a section of nNOS found in rats. The 
study identified the location of dNOS at position 32B on the second chromosome. dNOS 
comprises 19 exons and spans 34 kilobases of genomic DNA (Stasiv et al., 2001). 
dNOS encodes at least ten different transcripts expressed during Drosophila 
development and encodes for approximately seven different proteins (Stasiv et al., 
2001). However, only one of these proteins, dNOS1, is enzymatically active.  
dNOS1 is the only full length protein and its enzymatic activity is due to its carboxyl 
terminal reductase domain that the other truncated proteins lack. Additionally, Stasiv et 
al. (2004) showed that one of the truncated proteins, dNOS4, can inhibit the 
antiproliferative activity of dNOS1 in Drosophila larvae through ectopic dNOS4 
expression in the imaginal discs. Adult flies have a hyper-proliferative phenotype, 
indicating that dNOS1 function has been disrupted. The primary protein produced by 
dNOS, dNOS1, will be referred to as dNOS herein.  
Similar to nNOS and eNOS, generation of NO by dNOS occurs in a Ca
2+
- and 
calmodulin- dependent manner (Sengupta et al., 2003). In a biochemical analysis Ray et 
 
 
5 
 
al. (2007a) compared the oxygen domain of dNOS (dNOSoxy) with mammalian 
isoforms and concluded that dNOSoxy is most similar to the oxygen domain found in 
nNOS, except that they possess different kinetic properties. This similarity is 
corroborated in Regulski and Tully (1995) which reported a high degree of homology in 
protein structure between dNOS and the mammalian constitutively expressed NOS 
isoforms, nNOS and eNOS, with the former being the most similar in structure (43% 
sequence similarity).  
Interestingly, Ray et al. (2007a) also reported that computer models indicate this 
difference in kinetic properties enables dNOS to function more efficiently and actively 
in NO release when compared with mammalian isoforms. This may allow for increased 
diversity of signalling in Drosophila. Further biochemical comparison of the dNOS 
reductase domain and its associated calmodulin binding site also confirms the most 
significant similarity with those structures in nNOS (Ray et al., 2007b).  
Recently, Yakubovich et al. (2010) reported that NO is not required for normal 
development of Drosophila. This is in contrast to Regulski et al. (2004) which 
previously characterised a mutation in a conserved residue that the researchers believed 
completely abrogated NO activity. Regulski et al. (2004) reported that this lesion 
(NOS
c
), believed to be a NO null mutation, produced lethality. Upon further 
investigation, Yakubovich et al. (2010) stated that this is incorrect due to two factors: 
the mutation was not rescued once NO is reintroduced and the failure of Regulski et al. 
(2004) to generate deletions for all of the seventeen alleles identified in the NOS 
complementation group. Yakubovich et al. (2010) modified the knockout design, which 
included a lethal lesion, and found that a more accurate deletion of dNOS was not lethal 
in Drosophila; in fact, the flies appeared healthy, despite the deletion.  
1.1.8. Localisation of NO activity using the NADPH-diaphorase method 
The NADPH-diaphorase (NADPHd) staining method has been validated in many 
invertebrates, such as Drosophila, by purifying host NOS and demonstrating co-
localisation for NOS and NAPDHd activities (Müller, 1994). This technique is based on 
detecting an insoluble formazan precipitate produced by NADPHd and levels of 
staining correlate with NOS expression. In Drosophila Kuzin et al. (1996) used this 
technique to monitor dNOS activity and expression, which increased as development 
progressed in the developing imaginal discs. Initially, these increasing levels were 
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demonstrated in the eye, haltere, wing, and genital discs during the third instar; 
however, staining decreased in a specific spatial pattern once pupal development 
commenced. 
1.1.9. NO regulates growth and proliferation 
Stuehr and Nathan (1989) demonstrated that NO is a product of activated macrophages 
and has a cytostatic effect on its cellular targets while inhibiting respiration by 
damaging mitochondria. In an effort to further characterise this cytostatic effect, Kwon 
et al. (1991) identified ribonucleotide reductase (RR) as a potential target for NO, given 
its chemical properties. RR is a rate limiting step in DNA synthesis and NO is found to 
inactivate this enzyme in tumour cells, producing the cytostatic effect and reversibly 
inhibiting DNA synthesis. Thus, NO can ultimately slow growth by reducing rates of 
cellular division. 
In the developing Drosophila eye, NO is upregulated and acts in conjunction with RBF 
(Retinoblastoma-family protein) to promote antiproliferation by restricting entry into 
the S phase of the cell cycle (Kuzin et al., 1999). Wanga et al. (2007) also confirmed 
NO action in blocking cell cycle progression by restricting the G1-to-S phase transition, 
which resulted in G1 arrest. 
In Drosophila it has been shown that NO acts an antiproliferative agent during larval 
development (Kuzin et al., 1996). The adult fly is characterised by the size, shape and 
structure of its organs as a result of developmental processes that take place in the 
imaginal discs. Due to its role in limiting cell growth, it is thought that dNOS in 
Drosophila plays a pivotal role in development from a larval stage (Kuzin et al., 1996). 
The study suggested that NO expression is high in the developing imaginal discs. 
Ectopic expression of NO in larvae results in hypotrophy of the organs and limbs while 
inhibition of NO produces hypertrophy in these anatomical features. Kuzin et al. (1996) 
concluded that antiproliferation caused by NO action regulates the balance between cell 
proliferation and differentiation. In a study within our own lab, it was shown that for 
NO to have an inhibitory effect on growth in Drosophila the transcription factor 
dFOXO must be present (Kimber et al.).  
 
 
 
 
7 
 
1.1.10. NO donors  
Using the [
3
H]-thymidine incorporation technique, Magalhães et al. (2006) investigated 
the rate of DNA synthesis in chick retinal cells in culture. [
3
H]-thymidine is a 
radioactive nucleoside that is integrated into new DNA strands during mitosis. By 
measuring the levels of radioactivity in the DNA using a scintillation beta counter, 
Magalhães et al. (2006) were able to gauge the levels of proliferation that occurs in 
response to NO. Two NO donors, S-nitroso-N-acetyl-penicillamine (SNAP) and 
Spermine nitric oxide (SpNO) complex, were separately incubated with these cells and 
[
3
H]-thymidine incorporation observed. The study reported that this incorporation 
decreased by ≈ 70% in the presence of both donors and is thought to occur via S-
nitrosylation as dithiotreitol reverses [
3
H]-thymidine incorporation inhibition. SNAP 
also caused antiproliferation in purified glial cell cultures.  
However, Hu et al. (2002) demonstrated that using the [
3
H]-thymidine incorporation 
method as a measure of the effect of NO on DNA replication is inappropriate, since 
radioactivity is shown to promote apoptosis in cells.  This study showed that in the 
murine fibroblasts 3T3 cell line, dose-dependent inhibition of proliferation and DNA 
synthesis is caused by the radioactive isotope and not thymidine itself. Using a stable 
isotope, it demonstrated that experiments can use thymidine in conjunction with mass 
spectrometry as a non-radioactive indicator of DNA replication and cell proliferation. 
Ironically, the radioactive form of thymidine modifies the very parameter it is intended 
to measure. Orlov et al. (2003) supported this conclusion by confirming that [
3
H]-
thymidine-DNA labelling inhibits proliferation and induces apoptosis on its own in 
canine kidney epithelial cells and porcine aorta endothelial cells. Therefore, studies 
using this method can generate more accurate data by not using thymidine in its 
radioactive form.  
There are several alternatives to using [
3
H]-thymidine incorporation in order to measure 
the effect of NO on DNA synthesis. Flow cytometry has been used to measure the effect 
of SNAP in this lab by Kimber (2005) on Drosophila S2 cells as an alternative to 
radioisotopes. This study also demonstrates the antiproliferative effect of NO on cells. 
Additionally, 5-bromo-2’- deoxyuridine 5’-triphosphate (BrdUTP) can be used as a 
marker of DNA strand breaks and thus, replication.  
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1.1.11. NO function in Energy Expenditure and Metabolism 
Given that NO has been shown to increase mitochondrial biogenesis physiologically 
and pathologically in leukemia (Carew, 2004), researchers should therefore investigate 
its role in regulating mitochondria-associated processes such as energy expenditure and 
metabolism. These two processes are heavily associated with preserving good health in 
mammals.  
Deviations from normal functionality of these processes are shown to accompany 
medical conditions such as obesity, a result of caloric intake being greater than energy 
expenditure (Knott and Bossy-Wetzel, 2010). Additional conditions such as age-related 
disorders (cancer, cardiovascular disease, neurodegeneration and diabetes) are also 
associated with dysfunction of these two processes. Exercise and caloric restriction 
(CR) dieting increase fat and glucose metabolism, and mitochondrial function, which 
have been shown to negate these disorders, a fact that one would attribute to the benefits 
these two practices have on regulating energy expenditure and metabolism (Knott and 
Bossy-Wetzel, 2010). As a result of both of these therapies, increased longevity and 
decreased risk of age-related disorders are observed. Although the role of NO in 
exercise has not yet been fully uncovered, it increases mitochondria numbers and 
energy production, indirectly regulating fat cell differentiation, CR and obesity.  
 
1.1.12. Role of NO in Pathophysiology  
NO production can also be associated with pathophysiology when formed in excess. As 
mentioned above, high levels of NO production can prove toxic, a fact that is harnessed 
by cells belonging to the immune system to fight pathogens. This potential for toxicity 
indicates that NO could be involved in pathological processes and conditions. Research 
has found that NO can combine with superoxide anions (O2
-
) to yield peroxynitrite 
(ONOO
-
). In mitochondria, for example, this product stimulates the release of 
cytochrome complex (c) from the inner mitochondrial membrane, a process normally 
initiated in response to pro-apoptotic stimuli (Ghafourifar et al., 1999). Therefore, this 
NO-derived product can induce cell death and mitochondrial stress in several cell types, 
blocking Complexes I and IV in the respiratory electron transport chain (Knott and 
Bossy-Wetzel, 2009). Pacher et al. (2007) provides a comprehensive discussion of the 
role of NO in generating peroxynitrite and gives evidence to support its association in 
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many pathological conditions such as cardiac and vascular diseases, circulatory shock, 
inflammation, cancer, stroke, neurodegenerative disorders and diabetes. 
Specifically, NO has been known to react with protein-based cysteine residues to induce 
S-nitrosylation which can impair protein function (Stamler et al., 2001). Interestingly, in 
research concerning age-related neurodegenerative diseases, S-nitrosylation of this 
nature with a variety of proteins has been demonstrated to accompany stroke, 
Alzheimer’s and Parkinson’s (Knott and Bossy-Wetzel, 2009).  
1.1.13. Role of NO and peroxynitrite in causing cancer 
Ironically, NO is demonstrated to have both a causative and preventive effect in cancer 
research. There is substantial evidence that its causative properties are a result of its 
ability to form peroxynitrite, the primary agent linked with DNA damage which can 
lead to cancer. 
NO is shown to stimulate tumour angiogenesis through promoting angiogenic and 
lymphangiogenic factor expression, specifically vascular endothelial growth factor 
(VEGF) (Jenkins et al., 1995). NO accomplishes these processes by decreasing the 
expression of thrombospondin-1, an endogenous antiangiogenic factor (Ridnour et al., 
2005), and also by promoting the maturation of blood vessels by recruiting pericytes 
(Yu et al., 2005).  
Furthermore, NO has been linked with breast and colon cancer. It is strongly associated 
with enhanced migration and invasion observed in tumour cells via sGC- and MAPK- 
dependent signalling mechanisms (Orucevic, et al., 1999; Siegert et al., 2002; Jadeski et 
al., 2003). 
NO has also been associated with DNA damage, resulting in clonal transformations and 
mutations in the DNA (Pacher et al., 2007). Formation of peroxynitrite can trigger 
oxidative modifications in guanine (Niles et al., 2006) and guanine nitration (Sawa and 
Ohshima, 2006). In addition to chemically modified guanine, the DNA base has been 
shown to mutate to all of the other bases as a result of peroxynitrite reactions in 
mammals (Suzuki et al., 2002) and viruses (Neeley et al., 2004). Peroxynitrite also acts 
indirectly to damage DNA as it can target DNA repair enzymes such as 8-oxoguanine 
DNA glycosylase which is responsible for excising mutated 8-oxoguanine and is 
inactivated by peroxynitrite (Jaiswal et al., 2001). 
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There are also many studies which contradict these reports and identify the tumour-
suppressing activity of NO. In mice, iNOS knockouts are demonstrated to induce 
lymphomagenesis (Scott et al., 2001), tumourigenesis in the intestines (Dhar et al., 
2003) and sarcomagenesis (Hussain et al., 2004). Fukumura et al. (2006) reported that 
these contradictions can be explained by the activity of p53 (tumour suppressor) in cells 
containing NO, cellular sensitivity to NO, types of iNOS cells implicated, and the 
intensity and duration of NO exposure.  
Mutant mice with a modified adenomatous polyposis coli gene, normally demonstrate 
spontaneous polyp generation in the intestines. However, this phenotype can be rescued 
if combined with iNOS knockout genes or if iNOS is inhibited (Ahn and Ohshima, 
2001), suggesting a pathological role for NO-producing iNOS. Similarly, Kisley et al. 
(2002) showed that genetic ablation of iNOS in mice results in an 80% reduction of 
lung tumour formation induced via treatment with urethane. 
Both the physiological and pathophysiological roles of NO are thus well documented 
and key to investigating the role of this messenger molecule in cancer, age-related 
diseases, metabolism and mitochondrial function.   
1.1.14. Role of NO in treating cancer 
In spite of a great number of studies that have been conducted to licence NO-based 
treatments, only two types of NO donor drugs have been approved for clinical usage 
and neither of them have been applied to cancer. For reasons mentioned in the previous 
section, it is clear that clinical applications of NO must be carefully designed in order to 
avoid pathology. Its beneficial effects are often only possible in extremely small 
concentrations of NO (at the picomolar level) to avoid cytotoxicity (Miller and Megson, 
2007).  
Diazeniumdiolates (NONOates) are a class of NO drugs that several studies show to be 
promising anti-cancer treatments (Wu et al., 2001; Cai et al., 2003; Chen et al., 2006). 
JS-K is a terminal oxygen-protected NONOate generated by the US National Cancer 
Institute, and has been demonstrated by Shami et al. (2003) to impede tumourigenesis in 
a great variety of cancer cells while leaving healthy cells unaffected. NONOates are 
very promising for cancer therapy since they allow researchers to easily predict the rates 
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of NO-release. However, further research is necessary to ensure that the application of 
future NONOate-based NO donor drugs can be safely conducted. 
1.1.15. Using MAC-NOS to overexpress NO in Drosophila 
This study will use the mouse macrophage iNOS gene (NOS2) characterised in a UAS-
MAC-NOS construct to examine the function of NO in vivo. NOS2 will be expressed 
under the control of the GAL4-UAS system which allows for tissue-specific expression 
of NOS2 during a specific developmental stage in order to generate the appropriate 
phenotypes that can be subsequently analysed. Specifically, the subject tissue in this 
case is the salivary glands and the developmental stage analysed is the third instar 
(Brand and Perrimon, 1993). 
Lowenstein et al. (1992) stated that NOS2 produces a high NO output and does not 
require binding of Ca
2+
 or calmodulin in order to function. This is in contrast to the 
other isoforms (including dNOS) justifying the use of a UAS-MAC-NOS construct for 
analysing in vivo overexpression of NO without Ca
2+ 
and calmodulin being required. 
1.2. Significance of using Drosophila as a model for growth and cell proliferation  
The Drosophila genome has been fully sequenced and now a great deal of genetic and 
physiological data has been collected (Buckingham et al., 2004). Therefore, the 
Drosophila model has a well-developed genetic toolkit. In addition, flies can be easily 
and cheaply cultured and possess a short generation time which can be utilised to 
quickly investigate the effects of genetic manipulation on cell proliferation and growth 
during development. 
In development, DNA replication is necessary for cells to grow and differentiate into the 
different organ systems. In Drosophila the larval stage is specialised for growth and 
feeding. Prior to pupariation, the 3-4 days that larvae spend feeding is characterised by 
an increase in body mass of approximately 200 times (Church and Robertson, 1966). 
This is primarily a result of an increase in cell size as opposed to nutritional intake. 
Larval development salivary glands undergo endoreplication, a process characterised by 
DNA replication occurring in the absence of cytokinesis (Smith and Orr-Weaver, 1991).  
Endoreplication occurs for approximately ten rounds, resulting in polyploidy and also 
an increase in large nuclei contained in giant polytene chromosomes in third instar 
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larvae (Yao et al., 2008). This process leads to an increase in cell size, but not cell 
number. In this crucial stage of development, once staining procedures are conducted, 
the size of these salivary glands greatly facilitates investigation of their cellular structure 
and genetic content via different microscopes. Given that the scale of observation is also 
increased, any alterations to these components induced through genetic modifications 
can be more easily compared with the wild type. 
In Drosophila, growth is regulated by NO signalling and many components of the 
insulin signalling pathway, characterised by interactions between oncogenes and tumour 
suppressors.  
1.3. Insulin 
In mammals, the hormone insulin is synthesised and secreted by β-cells within the islets 
of Langerhans in response to increased levels of glucose and amino acids. It functions to 
regulate blood glucose homeostasis following a meal via signalling cells to uptake 
glucose in the blood and also in insulin-responsive tissues such as muscle, adipose and 
liver (Géminard et al., 2006). 
1.3.1. Insulin and diabetes 
Diabetes mellitus is a pathological condition characterised either by failure to synthesise 
insulin (type 1 diabetes) or the more commonly inheritable form characterised by 
reduced insulin sensitivity (type 2 diabetes); the latter is a multifactorial syndrome 
caused by a combination of genetic predisposition and environmental factors such as: 
aging, obesity and physical inactivity. In 2005 the prevalence of diabetes in the United 
States was estimated at 20 million people with 1.5 million new cases reported that year 
alone. Additionally, 90-95% of these cases are due to type 2 diabetes (Deshpande et al., 
2008). 
Diabetes is globally approaching epidemic proportions due to changes in human 
behaviour and lifestyle (Zimmet et al., 2001). As a result it is crucial to understand the 
insulin pathway as genetic defects that disrupt this molecular mechanism and its 
components can generate insulin resistance which account for the vast majority of 
diabetes cases. The insulin pathway is highly conserved in Drosophila and has been the 
focus of much research. This qualifies Drosophila as a suitable model organism in 
which the mechanism of the insulin signalling pathway can be manipulated and 
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characterised. A more well-defined insulin pathway can assist clinical therapeutic 
methods in humans, fostering better treatment or preventative measures in light of the 
prevalence of diabetes. 
The insulin/insulin-like growth factor (IGF) system (IIS) is split into two subsystems 
which complement and interact with each other to regulate growth, reproduction, 
metabolism and longevity (Nakae et al., 2001). IGF, a known downstream target of 
growth hormone, functions to regulate growth and cell size at both prenatal and 
postnatal levels. Additionally, both insulin and IGF are reported to bind and regulate 
physiological processes via the insulin receptor (Géminard et al., 2006). 
Géminard et al. (2006) also identified seven Drosophila insulin-like peptides (DILPs). 
These are expressed in separate tissues in Drosophila in insulin-producing cells (IPCs) 
and larval tissues such as the gut, imaginal discs and ventral nerve chord cells (Brogiolo 
et al., 2001).  Brogiolo et al. (2001) suggests that DILPs do not have redundant 
functions, given that they localise in different tissues; however, Rulifson et al. (2002) 
suggests that there might be some redundancy in their function by using gain of 
function experiments. Genetic ablation of the IPCs is documented to result in larval 
growth defects and increased longevity (Ikeya et al., 2002; Broughton et al., 2005) since 
DILP1, -2, -3 and -5 are produced in these cells. Yet, expressing DILP2 successfully 
rescues the phenotypes associated with the genetic ablation, which implies that 
redundancy is possible. Furthermore, Brogiolo et al. (2001) reported genetic interaction 
between dInR and DILP2 which is the most similar to insulin out of the seven DILPs. 
1.4. Insulin signalling pathway in Drosophila 
1.4.1. The Drosophila insulin receptor 
The insulin pathway commences when insulin and ILPs bind the InR. Components 
required in this pathway in mammals are reportedly conserved in Drosophila, with 
respect to the mechanism of signalling and regulation (Kozma and Thomas, 2002; 
Leevers, 2001). This level of conservation is astonishing when considering the 
evolutionary distance between these organisms.  
The Drosophila insulin receptor (dInR) has a 368-amino-acid COOH-terminal 
extension which comprises multiple tyrosine phosphorylation sites (Yenush et al., 
1996); dInR is also similar to human IR, but is larger in structure as a result of the 
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extension. These two receptors both have two α and β subunits and given the sequence 
similarities between them, it is perhaps unsurprising that dInR is demonstrated to bind 
mammalian insulin with substantial affinity (Petruzzelli et al., 1986). 
Additionally, dInR is required for development in Drosophila. Mutations to dInR are 
normally recessive embryonic lethal, confirming that this receptor is necessary for 
normal development in addition to growth (Fernandez et al., 1995). This is expected as 
binding dInR is the initial step in the insulin signalling pathway and also suggests that 
the receptor has multiple outputs.  
1.4.2. Chico recruits PI3K via dInR phosphorylation 
As the Drosophila homologue for vertebrate insulin receptor substrate (IRS) 1-4, Chico 
has a vital role in regulating growth and cell size autonomously. Similar to dInR 
mutants, null mutations for chico result in a decrease in size of over 50% in flies, when 
compared with the wild-type proportions (Böhnin et al., 1999). The study argues that 
this phenotype is due to the loss of chico function as a regulator of cell size and growth 
in Drosophila. Clancy et al. (2001) also confirmed that chico regulates lifespan by 
reporting an average increase of ≈ 48% in homozygotes. In the insulin signalling 
pathway, once dInR is bound by DILP, chico becomes phosphorylated and subsequently 
recruits phospho-inositide 3-kinase (PI3K). 
1.4.3. PI3K comprises Dp110 and p60 subunits 
PI3K activity is normally dependent on the availability of dietary protein/amino acids 
(Britton et al., 2002).  Dp110 codes for the Drosophila homologue of mammalian class 
1a p110 that encodes the catalytic subunit of PI3K. Mutations of this gene produce 
larvae that are reduced in size and do not continue to grow once they have entered the 
third instar (Weinkove, 1999). Dp110 is recruited through the SH2 domain found on its 
adaptor, p60. PI3K recruits and activates several downstream targets in the insulin 
pathway via the generation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3).  
1.4.4. PIP3 generation via PI3K 
When Chico binds to PI3K, this results in the stimulation of its kinase activity. PI3K 
subsequently phosphorylates the 3-position belonging to the inositol ring of 
phosphatidylinositol 4, 5-diphosphate (PIP2) which is also associated with the plasma 
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membrane. PIP3 is the result of this chemical reaction. Edgar (1999) noted that Chico is 
not required for PI3K activation, since dInR has several dPI3K-SH2 docking sites on its 
COOH-terminal extension.  
Serine-threonine kinase Akt (also known as protein kinase B (PKB)) and 
phosophoinositide-dependent kinase 1 (PDK1) are recruited to the plasma membrane as 
a result of PI3K activation. This association occurs via their pleckstrin-homology 
domains binding to PIP3 (Yang and Xu, 2011); therefore, PIP3 also recruits Akt to the 
plasma membrane. Lawlor and Alessi (2001) reported that its association with PIP3 
enables the phosphorylation and consequently, the activation of Akt via PDK1. 
1.4.5. PTEN antagonises PI3K to negatively regulate growth 
PTEN is a dual protein/lipid tensin and phosphatase homologue. It is the primary PIP3 
substrate and antagonises PI3K function by converting PIP3 to PIP2 (Huang et al., 1999). 
Therefore, PTEN activity negatively regulates growth, characterising the phosphatase as 
a tumour suppressor. In spite of a relatively high number of activating mutations 
demonstrated in p110α, loss of PTEN lipid phosphatase is associated with far more 
cases of activation of the PI3K pathway observed in many human cancers (Shaw and 
Cantley, 2006). PTEN mutations are most commonly observed in the phosphatase 
domain and are often germline or sporadic in nature (Myers and Tonks, 1997).  
1.4.6. AKT inactivates and destabilises dFOXO and TSC2 via phosphorylation 
Akt phosphorylation of FOXO generates a 14-3-3 protein binding site which causes 
dFOXO to become inactivated by sequestration in the cytoplasm. Essentially, the 
insulin pathway negatively regulates FOXO transcriptional activity as a tumour 
suppressor via Akt.  
Additional targets of Akt include the tumour suppressor tuberous sclerosis complex 2 
(TSC2). Similar to dFOXO, Akt binds to and phosphorylates TSC2 to control growth 
and cell size (Manning et al., 2002). When Akt phosphorylates TSC2, the TSC1-TSC2 
complex becomes unstable which results in the inability of TSC to inhibit the 
phosphorylation of d4E-BP and S6K by suppressing Rheb activity.  
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1.4.7. S6K and d4E-BP phosphorylation results in global translation initiation 
Once d4E-BP and S6K become phosphorylated, this catalyses global translation through 
inactivation and activation of the two molecular targets respectively. In its inactive form 
the translation initiator, eIF4E, is normally bound to d4E-BP which results in 
translational inhibition; however, once phosphorylated, d4E-BP undergoes a change in 
conformation, preventing its binding and inactivation of eIF4E. Target of rapamycin 
(TOR) is activated via Rheb and directly phosphorylates d4E-BP and S6K. Once 
phosphorylated, activated S6K further phosphorylates its target, S6, which is a 
ribosomal protein. This action results in the translation initiation of 5’ terminal 
oligopyrimidine tract mRNAs which facilitate protein synthesis required for cell size 
(Yang and Xu, 2011).   
Furthermore, dFOXO sequestration in the cytoplasm inhibits transcription of d4E-BP, 
which normally occurs when dFOXO is unphosphorylated (Junger et al., 2003). This 
results in the negative regulation of growth, previously mentioned. As a result, insulin 
signalling functions to promote growth and cell size through stimulating protein 
synthesis and by inhibiting tumour suppressors, dFOXO and TSC2. Fig.1.2. illustrates 
the interplay and relationships required for growth control in the insulin signalling 
pathway. 
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Fig.1.2. Insulin signaling pathway in Drosophila (adapted from (Jünger et al., 2003)). 
Here dFOXO protein activity is characterised in the insulin signalling pathway. When this 
pathway is activated, several phosphorylation events occur and dFOXO is subsequently 
inactivated by Akt via phosphorylation. When insulin levels decrease, dFOXO becomes 
dephosphorylated and is able to enter the nucleus and increase transcription of dInR and d4E-
BP. Increased expression of dInR enables the cell to become more sensitive to insulin and 
prepares the organism to take full advantage of insulin present in the next meal. In the 
meantime, d4E-BP upregulation acts to decrease protein synthesis via its inhibitory binding 
action with eIF4E. The specifics of the interactions between other relevant components of the 
insulin signalling pathway are previously discussed in this chapter.  
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1.5. dFOXO 
The FOXO family of transcription factors have been identified as tumour suppressors in 
many species and regulate growth under the control of insulin/insulin-like signalling. In 
mammals four primary FOXO members have been identified: FOXO1, FOXO3, 
FOXO4 and FOXO6. Caenorhabditis elegans has only one member, DAF-16. In 
Drosophila, a homologue of DAF-16 and FOXO4 has been identified as simply dFOXO 
(Puig et al., 2003).  
Recently research has shown that dFOXO is sensitive to insulin signalling and acts as a 
transcription factor, regulating a significant array of downstream targets. dFOXO is also 
regulated by Akt signalling which, when activated in the presence of insulin, can 
sequester dFOXO in the cytoplasm, negating its activity as a transcription factor in the 
nucleus (Puig et al., 2003). This is turn inhibits RNA transcription of normal dFOXO 
gene targets which code for proteins that have many regulatory functions, including   
cell cycle progression, metabolism, apoptosis and growth. However, when insulin levels 
are low and Akt is inactive, dFOXO is able to perform its transcriptional functions 
which have been shown to affect over 200 genes. One of these targets is the gene coding 
for dInR, which is upregulated by dFOXO once insulin levels are low, increasing 
sensitivity to insulin in preparation for the next meal (Puig et al., 2005).  
Another target of dFOXO that is upregulated by the transcription factor is d4E-BP 
which inhibits the translation initiation factor, eIF4E (Eukaryotic Translation Initiation 
Factor 4E). As a negative regulator of growth, dFOXO promotes the expression of d4E-
BP which binds to eIF4E, preventing it from binding to the mRNA 5’ cap of many 
different mRNAs (Gingras et al., 1999).  Thus the translation of proteins essential for 
promoting growth is inhibited via dFOXO action. In addition, dFOXO signalling via 
d4E-BP induces resistance to oxidative stress and starvation. 
Previous experiments in our laboratory investigated the relationship between dFOXO 
and NO. When NOS2 is expressed in third instar larval salivary glands, the organs 
become reduced in size and d4E-BP-LacZ staining is increased, suggesting that dFOXO 
has a role in this process due to the increase of d4E-BP expression (Kimber, 2005). In 
order to further elucidate this putative role, dFOXO mutants were generated along with 
NOS2 expression. The results show that the NOS2-induced size reduction is then 
suppressed along with a decrease in d4E-BP-LacZ staining, which suggests that NO 
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signalling is dependent on the presence of dFOXO. d4E-BP expression is also 
demonstrated to be reduced when using RNAi-NOS. When using RNAi-NOS third 
instar larvae also demonstrate hampered development as they are unable to progress to 
the pupal stage. Experiments that use NOS2 as a form of NO overexpression show that 
protein translation is inhibited; this is most likely as a result of NO signalling through 
dFOXO to increase d4E-BP and inhibit eIF4E action.  
1.6. dMyc 
The oncogenic Myc family of proteins operates as transcription factors which regulate 
growth, metabolism, proliferation, apoptosis and immortalisation in Drosophila and 
mammals. Drosophila Myc (dMyc) is encoded by the dimunitive (dm) gene and its 
function has been investigated by producing dm null mutants. These mutants exhibit a 
decrease in body size when compared with the wild type. Myc is thought to 
heterodimerise with Max in order to form stable compounds capable of binding DNA 
sequences which code for proteins associated with promoting growth (Gallant et al., 
1996).  
Additionally, Myc is thought to be a target of FOXO in the nutrient sensing pathway. 
During fasting, FOXO null mutants are characterised by low levels of Myc protein, 
implicating FOXO as a regulator of Myc expression (Teleman et al., 2008). Studies 
show that Ras, another oncogene, also exerts control over Myc expression. 
1.7. Ras 
Ras proteins are well documented in tumourigenesis and mutant forms are heavily 
associated with approximately 30% of human cancers (Giehl, 2005). Therefore, much 
research has attempted to characterise the oncogenic effects of Ras proteins and their 
effectors. Ras activation occurs once tyrosine kinase receptors bind growth factors and 
has GTPase activity. It can be inactivated once the GTP is hydrolysed, a process which 
can also be accelerated via GTPase activating proteins (GAPs) (Koh, 2006).  
When analysing the results of this experiment it will also be important to note that 
endogenous Ras and activated Ras mutations (such as Ras
V12835
) have been 
demonstrated to stabilise (Sears et al., 2000) and promote expression of Myc (Prober 
and Edgar, 2002), which would suggest that Ras overexpression experiments may also 
include effects from increased Myc expression. 
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1.8. Aim  
The aim of this project was to investigate growth regulation within Drosophila 
melanogaster salivary gland cells. Using Drosophila the role of NO and its inhibitory 
effects on growth regulation were compared with the wild type. In addition, the role of 
oncogenes, Myc and Ras, in regulating growth in these cells were also examined. 
Genetic manipulation techniques were utilised in order to elucidate the genetic and 
molecular mechanisms of growth inhibition via the tumour suppressor, dFOXO, and 
overexpressed NO using NOS2, and their potential interactions with the oncogenes. 
Three experimental procedures were be used in order to accomplish this; these methods 
are Axiophot microscopy, confocal microscopy and Transmission Electron Microscopy 
(TEM).  
Nuclei measurements were compared in order to measure the effects of NO and dFOXO 
on growth in the salivary gland cells using Zeiss Axiophot microscopy. Comparative 
analysis was conducted between null alleles relative to the wild type using homozygous 
and transheterozygous dFOXO null allele combinations. The null alleles were also used 
in combination with NOS2 to confirm the interaction described in previous work in the 
laboratory.  
Golgi and mitochondria were examined in wild type control lines. The effects of 
dFOXO, NOS2 and the oncogenes on the structure of Golgi and mitchondria were 
characterised using confocal microscopy to visualise the cellular structures.   
Using TEM microscopy wild type salivary gland cells were visualised in order to 
observe the normal structure and size of cellular components such as: endoplasmic 
reticulum, chromosomes, secretory vesicles and Golgi. The effects of NO were 
examined and compared with the wild type controller line. Myc and Ras were 
introduced separately and the effect of NOS2 was also examined in conjunction with 
each oncogene.  
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Chapter 2 
 
Materials and Methods 
 
2.1. General 
 
2.1.1 Fly Husbandry 
 
Drosophila stocks and crosses were cultivated on D+ food in plastic vials measuring 
8cm x 2.5cm and flies were contained by rayon balls or cotton wool. Developing flies 
were maintained at either 18°C or 25°C on a 12 hour light-dark cycle. Adults were 
anaesthetised using CO2. 3
rd
 instar larval salivary glands and adults were observed using 
a Nikon SM2645 dissecting microscope Microtec MFO-90 light source.  
 
D+ Glocuse Food Media 
 
Agar 40g 
 
D+ Glucose anhydrous 551g  (Fisher Scientific) 
 
Yeast 143g 
 
Sucrose 185g 
 
Maize meal 236g 
 
Nipagen 10%w/v 82mls 
 
Propionic acid 25mls 
 
Water 5500mls 
 
Method 
 
Anhydrous D+ Glucose and yeast were mixed into a paste by adding a small volume of 
water. Similarly, the maize and agar were also mixed with water and then brought to the 
boil in order to dissolve. Once dissolved, the paste was added and the combination was 
brought to the boil. The mixture was allowed to cool prior to being poured into glass 
bottles or plastic vials.  
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2.1.2. The GAL4-UAS system allows targeted gene expression in Drosophila 
 
Genetic manipulation can be achieved using a variety of methods; however, the GAL4-
UAS system has proved to be one of the most versatile and useful techniques as shown 
in Duffy (2002) who compared it to a swiss army knife. In Brand and Perrimon (1993) 
this bipartite system was used to overexpress genes in Drosophila. The gene of interest 
is regulated by an upstream activating sequence (UAS). This UAS element contains five 
GAL4 binding sites and once GAL4 is expressed and binds with the UAS sites, 
transcription of the gene of interest occurs in a pattern that correlates with the specific 
GAL4 pattern of expression. Therefore, the expression of the gene of interest via UAS 
is termed the responder line and the GAL4 line is called the driver, both of which 
correspond to parental lines in Drosophila.  
 
2.1.3. dFOXO 
BG01018
 
Experiments also analysed the effect of the FOXO hypomorph, dFOXO
BG01018
, 
described in Dionne et al. (2006). The study identified a transposon insertion, 
BG01018, while conducting a genetic screen for Drosophila mutants that differ in 
mortality when compared to the wild-type when infected with Mycobacterium marinum. 
The insertion is located ≈ 130 nucleotides upstream of the start codon for dFOXO and is 
reported to induce a mild loss of function for the gene. dFOXO
BG01018
 mutants were 
provided by Marc Dionne (Kings College London). 
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2.2. Nuclei  Staining and  Measuring  
 
Materials 
1xPBS (10xPBS: 1.37M  NaCl,  0.1M  Na2HPO4, 0.01M  NaH2PO4; pH7.4) 
4% Paraformaldehyde in 1xPBS 
DAPI : 1:20,000  in  1x PBS with  0.1%  Triton X-100 
Aquamount (Polysciences) 
 
Method 
Wandering third instar larvae were dissected for their salivary glands via the inversion 
technique and fixed in 4% paraformaldehyde for 20 minutes. Glands were subsequently 
washed in 2x 5minutes in 1x PBS. Then they were incubated in diluted DAPI solution 
for 15 minutes. The glands were subsequently washed 2x 5minutes in 1xPBS prior to 
dissection. Finally, they were mounted on slides using Aquamount and observed on a 
Zeiss Axiophot microscope at 40x.  
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2.3. Preparation of Larvae for Transmission Electron Microscopy 
 
 All larvae were grown at 25ºC and picked as wandering third instars. Salivary glands 
were dissected in Tissue Culture Medium (TCM) and then immediately transferred to 
fixative and processed for transmission electron microscopy (TEM) as follows: 
  
 Primary fixation in 2.5% (v/v) glutaraldehyde in Na Cacodylate/HCl buffer, 
0.1M, pH7.4 for a few hours at room temperature and then overnight at 4º C 
 Rinsed in Na Cacodylate/HCl buffer, 0.1M pH7.4 (X 4) over several hours 
 Salivary glands pipetted into clear eppendorfs Secondary fixation  in 1% (w/v) 
osmium tetroxide (OsO4) in Na Cacodylate/HCl buffer, 0.1M, pH7.4 for 2h at 
room temperature 
 Rinsed thoroughly in d/w (X 5), including an overnight rinse at 4º C 
 Dehydrated in an ethanol series: 50%, 75% and 3 X dried, absolute EtOH for 
20min each 
 Propylene oxide (PO; 2 X 20min) (a ‘transition’ solvent) 
 Into 50:50 PO/TLV (Taab Low Viscosity) resin overnight 
 Into complete TLV resin the next day 
 TLV resin changed several times over 3-4 days 
 Larvae oriented within plastic embedding moulds and polymerised overnight 
(16h) at 60deg C 
 
The following stages were completed with the assistance of Dr. Julian R. Thorpe. 
 
 Thin (100nm) sections were cut with an Leica Ultracut Ultramicrotome and 
collected upon TEM support grids 
 Sections were post-stained in 2% (w/v) aqueous, 0.22m-filtered uranyl acetate 
for 1h, followed by 15min in lead citrate 
 Sections were examined in a Hitachi-7100 TEM at 100kV and images acquired 
digitally with an axially-mounted (2K X 2K pixel) Gatan Ultrascan 1000 CCD 
camera 
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Chapter 3 
 
Investigating potential interactions between NO and   
oncogenes 
 
3.1. Introduction 
NO functions to inhibit proliferation and evidence suggests it signals through FOXO 
(Kimber, 2005), a known tumour suppressor. Therefore, this suggests that NO may have 
tumour suppressive activity, possibly negating the action of oncogenes. In this chapter 
potential interactions between NO and oncogenes, Myc and Ras, were investigated as 
they relate to growth and development of cellular structures in the salivary glands.  
 
3.1.1. Myc 
The Myc family of proto-oncogenes codes for transcription factors which comprise a 
basic helix-loop-helix zipper (bHLHZ) protein structure (Oskarsson and Trumpp, 2005). 
This family has been exhaustively researched; in recent years genome binding, genetic 
profiling and genetic analyses have revealed the scope of Myc action in Drosophila and 
mammals. Myc functions in normal cells to incorporate environmental signals into 
varied processes such as: growth, immortalisation, metabolism, differentiation, 
proliferation and apoptosis (Eilers and Eisenman, 2008). 
Myc is a well-established transcription factor with the ability to both activate and 
repress transcription of target genes (Oskarsson and Trumpp, 2005). The majority of 
genes that are stimulated by Myc are transcribed by RNA polymerase II; however, RNA 
polymerase I which encodes rRNA (Grewal et al., 2005) and RNA polymerase III 
encoding tRNA (Steiger et al., 2008) also have Myc-induced transcriptional roles. 
Additionally, the mechanism of activation of gene transcription by dMyc is conserved 
in vertebrates (Gallant et al., 1996). 
The control of gene expression by Drosophila melanogaster Myc (dMyc) is particularly 
important in ribosomal RNA (rRNA) synthesis especially during larval development. In 
ribosome biogenesis, rRNA synthesis is demonstrated to be a rate limiting step which 
varies depending on cellular growth status (Grewal et al., 2005). Myc induces gene 
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expression to promote cellular growth via ribosome biogenesis, protein synthesis and 
metabolism (Eilers and Eisenman, 2008).   
In Drosophila dMyc is encoded by the dimunitive (dm) gene. Flies with null dm 
mutations have phenotypes characterised by decreased body size and sterility in females 
as a result of degenerated ovaries (Gallant et al., 1996). A study by Pierce et al. (2004) 
investigating overexpression of dMyc revealed that the protein controls growth-
regulated gene expression.   The study concluded that cellular growth within Drosophila 
is dependent on the function of dMyc, and overexpression of dMyc results in an 
increase in nucleolar sizes and significant elevation in the level of nuclear DNA. 
 dMyc is able to heterodimerise with a similar helix-loop-zipper protein known as Max 
(Eilers and Eisenman, 2008). The heterodimers formed between Myc and Max are 
stable and are able to recognise and bind to specific DNA sequences. The particular 
sequence recognised by these stable heterodimers is known as the E-box sequence 
(coding-sequence CACGTG). This binding leads to the transcriptional activation of 
down-stream target genes (Gallant et al., 1996). 
Teleman et al. (2008) suggested that Myc is an effector of the target of rapamycin 
complex 1 (TORC1) by regulating transcription of TORC1 targets. Using a MEME 
motif search, the study investigated which motifs matched for sequences immediately 
upstream and downstream of genes regulated by rapamycin and discovered that the E 
box motif that scores the highest belongs to the Myc/Max transcription factors. Further 
investigation using the RNAi technique to deplete Myc reduces the expression levels of 
TORC1 targets, suggesting that Myc is required to control the genetic expression of 
TORC1 targets.  
Additionally, Teleman et al. (2008) established dMyc as a target of dFOXO in the 
nutrient-sensing mechanism. In wild-type Drosophila muscle tissue, dMyc mRNA 
levels decrease by 50% with normal expression of FOXO when fasting; however, in 
FOXO null mutations, dmyc mRNA was unaffected. This suggests that dFOXO inhibits 
dMyc expression levels to conserve energy in Drosophila muscle during fasting 
associated with low insulin levels. In contrast, dFOXO mutants express lower levels of 
dMyc protein in adipose tissue when compared with the wild-type; therefore, dFOXO is 
required for constant levels of dMyc in adipose tissue while fasting, but inhibits dMyc 
expression in muscle.  
 
 
27 
 
Furthermore, Bouchard et al. (2007) reported that FOXO impairs Myc-driven 
lymphomagenesis by directly binding to the Arf locus in Eμ-myc transgenic 
hematopoietic stem cells. In addition, Delpuech (2007) found that FOXO3a activation 
represses the expression of several previously identified Myc target genes in mammals.  
 
3.1.2. Myc, Stem Cells and Cancer  
The scope of Myc targets extends further to include embryonic stem (ES) cells (Kim et 
al., 2008). Takahashi and Yamanaka (2006) reported that c-Myc is included in a 4-
factor reprogramming set which enables somatic cells to become induced pluripotent 
stem (iPS) cells. Numerous studies indicate that although Myc is not absolutely 
required, it amplifies the capacity of the other 3 transcription factors of the 
reprogramming set (Sox2, Oct4 and Klf4) by a factor of 2-10 fold in stimulating the 
formation of iPS cells. Research has established that the magnitude of this augmentation 
depends on the cell type in which this occurs and analyses have been conducted for 
human and mouse fibroblasts, liver cells and mature B cells (Okita et al., 2007; 
Takahashi et al., 2007; Wernig et al., 2007; Hanna et al., 2008). Studies show that Myc 
is only briefly required for augmenting this reprogramming since ectopic expression of 
Myc does not occur once the iPS cells have been generated. These results suggest that 
utilising delivery vectors such as the adenovirus, which can transiently increase Myc 
expression, should be preferred instead of Myc overexpression when seeking to induce 
pluripotency in cells, since the overexpression can promote tumourigenesis in iPS cells 
(Eilers and Eisenman, 2008). 
 
3.1.3. Myc and NO 
NO has been demonstrated to inhibit proliferation in several cell types and promotes 
differentiation in neural cell precursors. In contrast N-Myc, a member of the Myc 
family, promotes proliferation and is negatively regulated when these neural cells are 
induced to differentiate via retinoic acid. Ciani et al. (2004) reported that NO inhibits 
the proliferation of neuronal cell precursors, instead promoting their differentiation by 
negatively regulating N-Myc in the presence of retinoic acid. This proliferative 
inhibition occurs both when using nNOS and/or an exogenous source of NO and could 
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possibly be used in cancer therapeutic strategies for treating neuroblastomas expressing 
N-Myc.  
Given that NO signals through FOXO, and dMyc expression is demonstrated to be 
regulated by dFOXO in a tissue-dependent manner (Teleman et al., 2008), this chapter 
investigates if NO has a similar effect on Myc expression by comparing the effect of 
Myc on cellular structures with co-expressed Myc and NO via NOS2.  
Scott (2009) investigated the potential interaction between dMyc and NOS2 by co-
expressing the two growth regulators in third instar larval salivary gland cells. dMyc 
and NOS2 were also expressed separately and a wild type line was used as a control. 
The results from this experiment are included below in Fig.3.1. 
 
Fig 3.1. Average size of salivary gland nuclei expressing dMyc and NOS2 (Scott, 2009). 
Flies with dMyc expressed alone were shown to have the largest nuclei measurements at 
approximately 33.0μm. Co-expression of NOS2 and dMyc was remarkably similar in size to the 
wild type at 22.9 μm; however, nuclei sizes were larger than the line expressing NOS2 alone. 
These results suggest that NOS2 has an inhibitory effect on the Myc-induced overgrowth 
phenotype (Scott, 2009). 
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3.1.4. Ras 
Ras proteins are essential components of many signalling pathways within cells, and 
mediate a wide range of cellular events. 
For the purpose of this project I will be briefly exploring the effect Ras has on cell 
growth regulation. 
It is well known that Ras is a proto-oncogene and that certain mutations in the Ras gene 
cause the normally functioning gene to become an oncogene. Mammalian Ras family 
members K-Ras, H-Ras and N-Ras are often reported to demonstrate such mutations in 
leukemia, for example, and account for 30% of human cancers (Giehl, 2005; Repasky et 
al., 2004). H-ras mutations are commonly associated with kidney and thyroid 
carcinomas; N-ras mutations are present in melanoma and hepatocellular carcinomas; 
K-ras mutations are frequently seen in pancreatic and colorectal carcinomas (Adjei, 
2001).  
3.1.5. Ras regulates cellular growth 
It has been shown that Ras is involved in cell growth, survival and differentiation in 
Drosophila and that mutant forms of Ras can be the basis for tumourigenesis within 
cells (Oskarsson and Trumpp, 2005). Halfar et al. (2001) tested the function of Ras in 
the Drosophila eye by inducing clones of ommatidial cells homozygous for the Ras
x7b 
null mutations. Indeed these clones couldn’t be recovered in the Drosophila adult eye, 
implying that Ras is necessary for growth, proliferation and survival. However, in the 
imaginal discs the study discovered that proliferation is possible in Ras
-/-
 cells, but with 
decreased growth rate. The study concluded that in addition to growth, Ras is essential 
for survival and differentiation in postmitotic cells in eye imaginal discs.  
Growth control by Ras in Drosophila is believed to be due to the inherent growth deficit 
in Ras
-/-
 clones and also via an inability to compete with the faster growing wild-type 
cells. Research has verified this conclusion in the Drosophila eye imaginal disc and the 
wing disc (Halfar et al., 2001; Prober and Edgar, 2000).  
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3.1.6. Ras increases dMyc expression 
Research suggests that Ras can stabilise Myc protein (Sears et al., 2000), yet until 
recently there was no evidence to suggest that Ras regulates Myc on a genetic level. In 
addition to promoting cell growth, Ras has been demonstrated to control cell fate 
specification in Drosophila and Caenorhabditis elegans (Rommel and Hafen, 1998). 
dMyc has not been shown to influence differentiation, but the fact that it is stabilised by 
Ras warranted further investigation into the interaction between the two oncogenes. 
Prober and Edgar (2002) utilised Ras
V12
, an activated form of Ras, to investigate the 
effects on dMyc expression. Using the Flp/Gal4 technique (Neufeld et al., 1998), the 
study generated clones of cells that express Ras
V12 
in the developing wing disc in order 
to discover which effector pathway the two oncogenes interact in. Additionally, Prober 
and Edgar (2002) used dMyc-specific antibody staining to gauge the expression of 
dMyc in the clones. Although expression of a Ras
V12
 mutant, Ras
V12G37
,
 
fails to 
upregulate dMyc expression, Ras
V12S35
 accomplishes this. Increased expression of dMyc 
is observed throughout the wing disc, although it was difficult to determine this in the 
wing pouch, which inherently has significant levels of endogenous dMyc. Ras
V12S35
 
(also known as Raf
GOF
) is a Ras
V12
 effector loop mutant demonstrated to specifically 
activate MAPK; thus, the study concludes that Ras
V12835 
acts through the Raf/MAPK 
pathway to activate dMyc.  
While showing that these Ras mutants can regulate dMyc expression, it was imperative 
to discover if this also occurs in endogenous Ras during development. Using FLP/FRT-
mediated mitotic recombination, Prober and Edgar (2002) produce ras mutant clones 
(ras
-/-
) in ras
+/- 
tissues via the ras
c40b
 allele which does not have an open reading frame 
(Schnorr and Berg, 1996). In order to determine if ras is required for normal dMyc 
expression the study used dMyc-specific antibody staining to observe expression levels. 
Staining intensity is substantially reduced in cells containing ras
-/- 
in the entire wing 
disc, even in the wing pouch. Therefore, this confirms that normal dMyc expression is 
Ras-dependent in the developing Drosophila wing disc.  
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3.1.7. Ras and NO 
While investigating the role of MAPK pathways in nNOS induction, Schonhoff et al. 
(2001) demonstrated that Ras must function correctly if NO is to be produced in 
differentiating PC12 cells. The study infected these cells with a dominant negative Ras 
adenovirus and introduced nerve growth factor which is shown to increase nNOS 
expression. However, nNOS does not show activity under these circumstances, which 
suggests that Ras regulates nNOS production in these cells.  
Similarly, this present study will also examine the potential interaction between Ras and 
NO in salivary gland cells. This experiment will generate flies expressing activated Ras 
using Ras
V12
 separately and then co-express Ras
V12
 with NOS2 under the control of the 
GAL4 driver, c147. Any potential effects on cellular structures will be compared with 
the wild-type. Third instar larvae will be dissected for their salivary glands and cellular 
structures visualised using TEM.  
The incentive for conducting this experiment is derived from combining the findings of 
research examining the effect of NO and Ras
V12 
on gene expression separately. Previous 
work in the laboratory reported by Kimber (2005) described microarray data from 
Drosophila S2 cells treated with a NO donor and compared the results to untreated S2 
cells. Asha et al. (2003) analysed microarray data of Ras
V12
 expression compared with 
wild-type Ras expression in haemocytes. Scott (2009) describes an inverse correlation 
documented in these two studies regarding the promotion and suppression of genes 
regulated by Ras and NO that were identified. Ras
V12
 upregulates 1286 genes in 
haemocytes (Asha et al., 2003); however, 83 of these genes are downregulated by the 
NO donor (Kimber, 2005). The magnitude of the upregulation of these common genes 
by Ras
V12
 is indirectly proportional to their downregulation via the action of the NO 
donor (Scott, 2009), suggesting a proportionately opposite effect between the two 
transcriptional regulators.  
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Scott (2009) investigated the potential NOS2 suppression of Ras
V12
-induced growth in 
salivary gland nuclei. The study used an average of late third instar, wild type salivary 
nuclei sizes as a control and compares the measurements with NOS2-induced growth 
inhibition and Ras
V12
-induced growth promotion separately, in addition to co-expression 
of Ras
V12
 and NOS2. The results are illustrated in Fig. 3.2. below:  
 
Fig. 3.2.Average size of salivary gland nuclei expressing RasV12 and NOS2 (Scott, 2009). 
Fig.3.2. illustrates that the Ras
V12
 line had the largest nuclei measurements when compared with 
the other lines. Co-expressed Ras
V12 
and NOS2 produced nuclei that were smaller than both the 
wild-type and Ras
V12 
line, but larger than the NOS2 line. This showed that NOS2 acts to dilute 
the overgrowth phenotype demonstrated by Ras
V12 
activity. The results can also be interpreted 
as Ras
V12
 acting to suppress the growth inhibition phenotype of NOS2. Nevertheless, the 
opposite effects that both these growth regulators had on nuclei sizes correspond with the 
findings from Kimber (2005) and Asha et al. (2003) (Scott, 2009). 
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3.2. Results 
This chapter intends to complement the findings reported in Scott (2009) by examining 
the effect of the oncogenes, Myc and Ras, when combined with NOS2. Similarly, this 
experiment will focus on the salivary gland as a model for this co-expression; however, 
instead of investigating nuclei growth, the cellular structures in salivary glands were 
visualised using TEM and compared with the wild type. Effects on the structure of 
nuclei, polytene chromosomes and secretory vesicles as a result of co-expressing NOS2 
and the oncogenes were visualised. Forty five animals from each genetic cross were 
dissected and then eight glands were selected randomly for TEM visualisation.   
3.2.1. Wild type and NOS2 
Fig. 3.3 shows that nuclei sizes were reduced in the NOS2 line compared with the wild 
type. Given that NO is demonstrated to inhibit growth and proliferation, these results 
were expected. Interestingly, secretory vesicles that were clearly present in the wild type 
were not visible in lines expressing only NOS2. Whether this was a result of the 
vesicles becoming too small to visualise or if the action of NOS2 completely inhibited 
the development of any secretory vesicles is unclear.  
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Fig.3.3. Wild type (c147-GAL4/+): (A and C) Wild type nuclei, polytene chromosomes and 
secretory vesicles were visualised on the left. 
Overexpression of NOS2 (UAS-NOS2; c147-GAL4): (B and D) Nuclei and polytene chromosomes 
from flies that overexpressed NO are shown on the right.  
*Yellow arrows (          ) identify polytene chromosomes; red arrows (          ) indicate secretory 
vesicles. Scale bars 2µm. 
 
 
 
 
  
  
A B 
C D 
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Fig.3.4. Overexpression of NOS2 (UAS-NOS2; c147-GAL4): (A-D) Images of the nuclei and 
polytene chromosomes for flies expressing NOS2 were generated. These images were visualised at a 
higher magnification (2500X) to provide more detail. Scale bars 1µm.  
 
                                                                              
  
  
A B 
C D 
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3.2.2. Ras
V12
 
In order to explore the effect of NOS2 on the overgrowth phenotype documented in 
Ras
V12
 activity, this experiment sought to co-express these two growth regulators. The 
images produced by introducing Ras
V12 
co-expression with NOS2 (Fig.3.5.) were 
similar to the results found with dMyc and NOS2 (Fig.3.6). When expressed on its own, 
Ras
V12
 induced an overgrowth phenotype in nuclei, chromosomes and secretory vesicles 
(Fig.3.5.). 
Co-expression of Ras
V12
 and NOS2 (Fig.3.5.) produced smaller cellular structures when 
compared with the wild type and Ras
V12
 alone, as seen in Scott (2009) which measured 
salivary gland nuclei size; however, structures were larger than those observed in lines 
expressing only NOS2 (Fig.3.4.). Unexpectedly, the ER in this co-expression 
experiment appears to be largely absent when compared with the wild type. Small 
portions of ER in proximity of the nucleus are visible, but in much smaller quantities. 
The outer membrane of the nucleus also appears to be budding (Fig.3.7.). 
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Fig. 3.5. Activated Ras
V12
 (c147-GAL4/UAS-Ras
V12
): (A and C) Nuclei, chromosomes and secretory 
vesicles from animals expressing activated Ras are shown on the left.Coexpression of Ras
V12
 + 
NOS2 (NOS2/+; c147-GAL4/UAS-Ras
V12
): (B and D) Chromosomes, nuclei and secretory vesicles 
are illustrated from animals expressing both Ras
V12
 and NOS2.  
*Yellow arrows (          ) identify polytene chromosomes; red arrows (          ) indicate secretory 
vesicles; blue arrows (          ) represent a malformation in the outer nuclear membrane; green arrows (           
) represent the ER. Scale bars 2µm.
  
  
B A 
C D 
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3.2.3. dMyc 
As dMyc expression has been reported to increase cellular growth, it was expected that 
lines expressing only dMyc only would have the largest cellular structures. 
Furthermore, lines expressing only NOS2 had the smallest structures, which was also 
expected given that NO induces growth arrest (Gibbs, 2003).  
When salivary gland cellular structures from flies co-expressing NOS2 and dMyc were 
visualised (Fig.3.6.), it was noted that the average structural sizes of cellular 
components appeared to be smaller than the wild type (Fig.3.3.). Apart from a reduction 
in size, nuclei, secretory vesicles and chromosomes appeared to be normal. It is 
interesting to note that ER formation was very similar to the lines co-expressing Ras
V12
 
and NOS2 (Fig. 3.5). The connection between the outer nuclear membrane and the ER 
membrane was poorly defined and resembles budding from the outer membrane of the 
nucleus. ER structures are mostly absent and appear to have either been degraded or not 
well developed (Fig.3.8.). 
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Fig. 3.6. Overexpression of dMyc (c147-GAL4/+; UAS-dMyc/+): (A and C) Polytene 
chromosomes, nuclei and were visualised in flies overexpressing dMyc on the left. 
Coexpression of dMyc and NOS2 (NOS2/+; c147-GAL4/+; UAS-dMyc/+): (B and D) These 
structures were also visualised in lines co-expressing dMyc and NOS2 shown in the images on the 
right.   
*Yellow arrows (         ) identify polytene chromosomes; red arrows (           ) indicate secretory 
vesicles; blue arrows (         ) represent a malformation in the outer nuclear membrane. Scale bars 
2µm. 
 
 
A B 
C D 
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Fig. 3.7. Coexpression of Ras
V12
 and NOS2 (NOS2/+; c147-GAL4/UAS-Ras
V12
).These images were 
visualised at a higher magnification (2500X) to provide more detail.  
Blue arrows (          ) represent a malformation in the outer nuclear membrane. Scale bars 1µm. 
 
 
  
 
Fig. 3.8. Coexpression of dMyc and NOS2 (NOS2/+; c147-GAL4/+; UAS-dMyc/+): These images 
were visualised at a higher magnification (2500X) to provide more detail. 
 Blue arrows (          ) represent a malformation in the outer nuclear membrane. Scale bars 1µm.  
 Note that ER formation was very similar to the lines co-expressing RasV12 and NOS2
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3.3. Discussion                                                                                                                                                                                                                                                                                                                                                                               
3.3.1. dMyc             
The mechanism behind the interaction between NO and dMyc is currently not clearly 
defined; however, the results indicate that NO expression can act to almost completely 
reduce the overgrowth phenotype associated with dMyc. In neuronal cell precursors 
Ciani et al. (2004) demonstrated that NO inhibits proliferation to instead promote 
differentiation through negatively regulating N-Myc expression when retinoic acid is 
present. This demonstrates that NO can act as an antiproliferative agent. This study 
suggests that NO signalling can negatively regulate dMyc-induced growth through 
FOXO.  
Other studies have highlighted FOXO inhibition of dMyc expression which may explain 
the results seen in dMyc and NOS2 co-expression here, given that NO is demonstrated 
to signal through dFOXO (Kimber et al.). In Eμ-myc transgenic hematopoietic stem 
cells, Bouchard (2007) reported that FOXO acts to negate the oncogenic action of Myc 
by binding to the Arf locus. Delpuech (2007) also explored the interaction between the 
two and found that FOXO3a activation negates Myc activity by inhibiting the 
expression of several Myc target genes. Moreover, Teleman et al. (2008) reported that 
dMyc mRNA levels are reduced by 50% when FOXO is normally expressed during 
fasting in Drosophila muscle tissue, which is also confirmed in Demontis and Perrimon 
(2009).  
3.3.2. Ras    
As previously mentioned Ras
V12 
and NO both regulate the expression of 83 common 
genes, demonstrating an opposite effect on the transcription of these genes (Asha et al., 
2003; Kimber, 2005). Scott (2009) also examined the co-expression of Ras
V12
 and 
NOS2 by measuring the salivary gland nuclei sizes and finds that co-expression of the 
two produces nuclei sizes that lie in between values measured when they are expressed 
separately. From these studies, it can be concluded that co-expression mutes the more 
extreme effects of both growth regulators.  
As demonstrated in Figs. 3.7. and 3.8., which show co-expression of NOS2, and Myc 
and Ras
V12
 separately, the endoplasmic reticulum, which can be observed in proximity 
to the nucleus in the wild type, NOS2 and oncogene lines, is largely absent when NOS2 
is co-expressed with each oncogene. Yang et al. (1997) described normal development 
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of the nuclear envelope as a specialised subcompartment of the ER. In the cell this 
would normally consist of nuclear pore complexes, the nuclear lamina, and outer and 
inner membranes. In fact the outer nuclear membrane is normally continuous with 
smooth and rough ER located in proximity to the nucleus, forming an interconnected 
boundary (Subramanian and Meyer, 1997). However, in this experiment, the ER 
membrane connecting the ER and the nuclear envelope appears to be partially formed, 
resembling budding from the outer nuclear membrane. 
Given that only co-expression of these oncogenes and NOS2 show this phenotype, this 
study aims to investigate potential interactions between these compounds that would 
affect the ER in such a manner. Using the available literature this study concludes that 
ER stress may be manifested by the combination of these oncogenes and NO as 
alternatives are not available.  
As previously mentioned in Chapter 1, the toxic oxidant, peroxynitrite, is formed when 
NO and superoxide react at physiological pH. Dickhout et al. (2005) reported that 
peroxynitrite can cause endoplasmic reticulum stress and apoptosis in human vascular 
endothelial cells. Peroxynitrite is also implicated in human atherosclerosis, since its 
marker, 3-nitrotyrosine is upregulated in atherosclerotic lesions. 
In this experiment, since NO was generated in abundance by NOS2, this paper 
investigates whether NO, Ras
V12 
and/or dMyc can produce superoxide, a ROS, in order 
to drive peroxynitrite formation that can cause ER stress. 
3.3.3. Myc increases production of ROS 
Vafa et al. (2002) reported that c-Myc can increase ROS in normal human fibroblasts, 
which can induce DNA damage. Given that Myc has many targets, it is difficult to 
pinpoint a mechanism through which it can increase ROS production. The study states 
that it is likely that ROS is produced as a result of biochemical imbalances that occur 
due to the effect of oncogenic Myc inducing unusual synthesis of a large number of 
gene products. 
The dMyc gene used in this experiment has only 26% amino acid sequence similarity to 
c-Myc (Gallant et al., 1996). However, when conducting a protein database search, 
dMyc shows significant homology with the mammalian oncogene regarding its 
functional regions. Its NH2-terminus shows 57% similarity with c-Myc, and mutations 
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in the region usually abolish Myc action. 57% similarity is also seen in its acidic region 
and 40% in its COOH-terminal sequence (Gallant et al., 1996). In addition, dMyc is 
capable of restoring the proliferative function of c-Myc null mutants and co-
transforming primary mammalian cells (Trump et al., 2001). Therefore, there are 
sufficient molecular similarities that qualify Drosophila as a good model when 
comparing the two Myc proteins (Orian et al., 2003). 
 
3.3.4. Ras
V12
 is involved in generation of ROS necessary for Ras transformation 
Oncogenic Ras is believed to produce ROS during Ras transformation, but little is 
known about the mechanism through which this occurs. Oncogenic Ras is shown to be 
linked to superoxide generation in transformed fibroblasts (Mitsushita et al., 2004) and 
Choi et al. (2008) reported that a BLT-Nox1-linked cascade may be the mechanism 
through which this occurs via H-Ras
V12
. Ras transformation can be inhibited via 
antioxidants (Irani et al., 1997); therefore, it is necessary for Ras to depend on super 
oxide production in order to undergo transformation and escape inhibition by 
antioxidants. 
To conclude, in this Chapter the results indicate that NO decreased the size of cellular 
structures and polytene chromosomes. Additionally, secretory vesicles were not clearly 
visible in these lines expressing NOS2. When NO was co-expressed with each 
oncogene (Myc and Ras
V12
), cellular structures were also smaller than the wild type. 
Furthermore, secretory vesicles were visible, but reduced in size. Interestingly, 
combining NO with the oncogenes appeared to have an effect on the formation of ER 
which suggests that ER stress was induced. This study suggests that the combination of 
NO and the oncogenes acts to induce ER stress through the formation of ROS which 
combines with NO to produce peroxynitrite, a toxic oxidant known to generate ER 
stress. 
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                                                                        Chapter 4 
 
    dFOXO Mediates NO Signalling in the Regulation of 
Cellular Growth 
4.1. Introduction  
4.1.1. Conservation of the FOX family: an introduction to FOXO  
The forkhead box (FOX) gene family of transcription factors is characterised based on a 
conserved DNA-binding domain, consisting of a 110-amino acid motif. X-ray 
crystallography examining this domain has defined a three-dimensional structure 
containing three α-helices which are flanked by two distinctive loops resembling 
butterfly wings (Friedman and Kaestner, 2006). Consequently, the highly conserved 
DNA-binding motif is often described as a ‘winged-helix’ structure.  
In humans, the FOX family has over 100 members, ranging from FOXA-R, with the 
nomenclature based on sequence similarity. The term ‘forkhead’ is originally coined in 
Drosophila as the name of a gene that, when mutated, produces a phenotype of ectopic 
head structures with a characteristic spiked head appearance resembling a fork. This 
gene that was originally discovered is now characterised as FOXA (Myatt and Lam, 
2007).  
However, this study will focus on the ‘O’ class of FOX proteins, members of which 
share the distinction of being regulated by the insulin/PI3K/Akt signalling pathway. 
Structurally, this class is distinguished from the other classes by an insert of five amino 
acids present in the DNA-binding domain that play an important role in sequence-
specific interaction with binding sites. Most of the other FOX proteins bind consensus 
sequences that share the core sequence (A/C)AA(C/T) whereas FOXO proteins bind 
(T/C)(G/A)AAACAA (Myatt and Lam, 2007). This distinction gives the FOXO class a 
mechanism for preferentially binding with a specific group of target sites in a genome. 
Drosophila FOXO (dFOXO) is the singular FOXO gene in Drosophila as opposed to 
mammals which have three highly related FOXO genes (1,3 and 4) (Barthel et al., 
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2005). Furthermore, dFOXO has significant sequence similarity with the mammalian 
members of the FOXO family in the forkhead domain (Jünger et al., 2003).  
There is substantial evidence indicating that FOXO proteins have an evolutionarily 
conserved role as mediators of the effects of insulin and growth factor signalling on a 
variety of physiological functions. These include apoptosis, cell proliferation, oxidative 
stress resistance and metabolism.  
4.1.2. FOXO is a downstream component of the insulin signalling pathway 
The insulin signalling cascade is initiated via binding at the insulin receptor (InR). The 
downstream events are numerous; however, this study will concentrate on one aspect of 
this cycle that modulates gene expression via the FOXO protein discussed below (Puig 
and Tijan, 2005). Signalling from the insulin receptor is mediated by two pathways: 
either the PI3K/AKT cascade or the Ras/MAP cascade (Puig et al., 2003). It is via the 
PI3K/AKT pathway that the FOXO proteins are utilised in modulating gene expression. 
(Puig and Tijan, 2005).  
4.1.3. AKT regulates FOXO by inhibiting its transcriptional activity 
 Once insulin binds to the InR, PI3K is subsequently activated; this triggers a cascade of 
signals and events within the cell which will ultimately lead to growth regulation (Puig 
et al., 2003). Activated PI3K leads to an increase in the amounts of PIP3 
(phosphoinositide lipids) available in the cell, acting as relay molecules or second 
messenger molecules, to propagate the signal along the cascade. As a result of the 
increase in PIP3 production, Akt is localised to the plasma membrane of the cell and is 
subsequently phosphorylated. This phosphorylation leads to Akt becoming activated 
and enables it to phosphorylate other components of the signalling cascade which lie 
downstream, one of which is FOXO (Puig et al., 2003). 
 Akt phosphorylates FOXO at three conserved serine/threonine residues, which causes 
FOXO to be kept within the cytoplasm of the cell, thus inhibiting DNA binding via its 
forkhead box and decreasing RNA synthesis (Puig et al., 2003). As a result Akt is able 
to regulate gene expression by negatively regulating the action of FOXO (Puig and 
Tijan, 2005). 
 The result of this cascade is that many cellular events and components are affected; 
these include: cell cycle progression, metabolism, apoptosis, growth and general 
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survival of the cell. Puig et al. (2003) concluded that within Drosophila, this cascade 
can control cell size, life span and overall body size. 
4.1.4. Activated FOXO functions as a tumour suppressor  
Additionally; FOXO has been associated in immunology and diseases such as cancer. In 
mammals, Paik et al. (2007) demonstrated the importance of FOXO transcription 
factors in preventing cancer. When performing broad somatic deletions for several 
FOXO alleles (1, 3a and 4), mice developed lymphomas and haemangiomas. Yet when 
performing these deletions for each allele separately, neoplasia is significantly reduced. 
The study suggests that although FOXOs can negatively regulate tumour growth, this 
function is redundant among FOXO subtypes. 
Furthermore, FOXO inactivation has been linked to breast cancer, the second leading 
cause of cancer death in women. Kong et al. (2010) reported that microRNA-155 (miR-
155), often expressed at high levels in breast cancer, targets and inhibits FOXO3a. This 
regulation of FOXO3a by miR-155 is determined by overexpressing miR-155 which 
then represses FOXO3a protein action. The reverse proves to be true as miR-155 
knockdown increases FOXO3a activity.  miR-155 appears to directly inhibit FOXO3a 
through binding to it rather than via phosphorylation. Kong et al. (2010) showed that 
ectopic expression of miR-155 acts to promote cell survival and increase 
chemoresistance. miR-155 knockdowns increase apoptosis (as a consequence of 
FOXO3a being uninhibited) and chemical sensitivity in cells (Kong et al., 2010). 
Therefore, miR-155 should be considered a target of breast cancer therapy.   
FOXO proteins have been associated with processes that inhibit growth and even 
contribute to cell death via apoptosis (Barthel et al., 2005).  Puig et al. (2003) 
demonstrated that dFOXO acts to both stimulate and inhibit components of the insulin 
pathway in which insulin acts as an indicator of nutritional load.  
4.1.5. FOXO regulates InR transcription in a feedback mechanism and is a sensor 
for insulin 
Puig et al. (2005) showed that the insulin signalling pathway includes a feedback 
mechanism in which InR synthesis is regulated by dFOXO in flies and FOXO1 in 
mammals. These transcription factors function to initiate transcription of InR during 
fasting. In Drosophila this was demonstrated by initiating starvation which 
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consequently increased mRNA expression levels of dInR in normal flies; however, 
dInR mRNA levels were unaffected in starved dFOXO null mutant flies. Similarly, InR 
mRNA levels in mammals are increased via FOXO1 DNA-binding action once 
starvation is induced. In addition to the dInR mRNA increasing during starvation, there 
is a parallel increase in dInR protein levels (Puig et al., 2005).  
These corresponding results strongly support the theory that the FOXO transcription 
factors act in mammals and Drosophila as ‘insulin sensors’ to prepare the insulin 
signalling pathway. Insulin sensitivity is greatly increased during fasting simply because 
of the increase in its receptors by dFOXO and in the PI3K/AKT pathway. Upon 
feeding, the presence of insulin triggers Akt to phosphorylate dFOXO which sequesters 
it in the cytoplasm. dFOXO is unable to enter the nucleus to bind with the dInR 
promoter and dInR mRNA and protein levels fall, reducing insulin sensitivity. This is 
perhaps an adaption to permit a rapid response to insulin in fasting organisms so that 
they can take full advantage once a meal has been consumed (Puig et al., 2005).  
Similarly, dFOXO has also been found to upregulate the transcription of d4E-BP (also 
known as Thor) which is a protein which binds to the translation initiator, eIF4E. 
4.1.6. dFOXO controls d4E-BP transcription 
A component of the eIF4F protein complex, eIF4E binds to the mRNA 5’ cap of many 
eukaryotic mRNAs to initiate translation of proteins (Gingras et al., 1999). eIF4E 
activity is in turn negatively regulated by the binding action of eIFE-binding protein 
(4E-BP), one of the binding partners of eIF4E  (Haghighat et al., 1995). As a result, in 
the presence of unbound eIF4E, abundant 4E-BP expression results in decreased 
translation initiation of many mRNAs via its negative regulatory binding action on 
eIF4E. 4E-BP is further characterised as a downstream effector of the TOR/PI3K 
signalling pathway.  Once flies are subjected to oxidative stress, such as hydrogen 
peroxide exposure, their survival can be maintained by adequate 4E-BP activity; 
therefore, this protein can heavily influence lifespan under such stress (Zinke et al., 
2002).  Dietary restriction has a similar effect since a lack of nutrients inhibits the target 
of rapamycin (TOR) pathway that would otherwise phosphorylate 4E-BP. In this case 
since 4E-BP is unphosphorylated, it is free to bind with eIF4E and negatively regulate 
translation. 
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In Drosophila d4E-BP transcription is activated by dFOXO. However, once activated, 
the PI3K pathway promotes Akt action which in turn, phosphorylates dFOXO, 
preventing it from entering the nucleus and upregulating transcription of d4E-BP (Puig 
et al., 2003).  This shows the regulatory effect that Akt activity can have on d4E-BP by 
controlling it via dFOXO at the levels of gene transcription and translation. 
The evidence of this relationship between dFOXO and d4E-BP led Tettweiler et al. 
(2005) to further investigate how critical the presence of d4E-BP is to survival once 
flies are subjected to poor nutrition and oxidative stress. Indeed the study indicated that 
ectopic expression of d4E-BP, induced in flies with dFOXO null mutations, can 
overcome oxidative stress and fully rescue oxidative stress sensitivity in the absence of 
dFOXO. This provides further evidence that d4E-BP is important for survival under 
stressful conditions and can act independently of dFOXO. Additionally, given that 
dFOXO overexpression correlates with increased longevity when subjected to oxidative 
stress (Giannakou et al., 2004), Tettweiler et al. (2005) suggested that d4E-BP 
expression can also control lifespan independently of dFOXO, even though dFOXO 
increases its expression.  
4.1.7. FOXO regulates the immune system 
Recently, FOXOs and other FOX classes have been demonstrated to function crucially 
in several aspects of immunity. This study will focus on the FOXO class for the 
purposes of this discussion, investigating the current understanding of the role of FOXO 
in immunity. 
Coffer and Burgering (2004) examined the connection between FOXO and the immune 
system in the mammalian model by inducing FOXO3a null mutations in mice. The   
FOXO3a
-/-
 mice exhibit “spontaneous lymphoproliferation, mild multi-system, non-
lethal inflammation, TH1- and/or TH2-cell hyperactivation, NF-κB hyperactivation and 
cytokine overproduction”. These results indicate that the role of FOXO3a in immunity 
is to control lymphocyte proliferation and apoptosis, suppress T-cell activation and 
negate autoimmunity (Coffer and Burgering, 2004). 
An additional role of FOXO in the immune system is described in Becker et al. (2010) 
which showed an evolutionarily-conserved role of FOXO in regulating antimicrobial 
peptides (AMPs). These immune effector molecules are important in fighting infection 
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in animals and plants (Bulet et al., 2004). In Drosophila FOXO is shown to activate 
AMPs independently of their normal immunoregulatory pathways. This was 
demonstrated by testing FOXO null mutants and FOXO overexpression for AMP 
induction. Null mutants exhibit a loss of AMP induction while the overexpression 
studies show that AMP is greatly enhanced in this case. In Drosophila and humans, 
FOXO-dependent regulation of AMPs that combat infection is thought to be 
evolutionarily conserved (Becker et al., 2010). 
4.1.8. Previous studies in the laboratory investigating interactions between NO and 
dFOXO 
A previous study in our laboratory conducted by Kimber (2005), investigated the 
possibility of interaction between nitric oxide (NO) and dFOXO in the insulin signalling 
pathway using dFOXO loss-of-function mutants (null alleles), dFOXO
21 
and dFOXO
25
. 
These mutations were also co-expressed with UAS-RNAi NOS and UAS-MAC-NOS 
separately. The alleles were induced by the mutagen ethyl methanesulfonate (EMS) 
which generates point mutations in dFOXO
21 
and dFOXO
25
 and converted codons W95 
and W124, respectively, to stop codons, disrupting dFOXO function (Jünger et al., 
2003).  
With the purpose of evaluating the effects of expressing UAS-RNAi NOS and UAS-
MAC-NOS on Thor expression in a null dFOXO background, the experiment used Thor 
reporter staining to visualise this expression. The c147-GAL4 line was used to drive 
expression of the transgenes only in the salivary glands.  
Observing the progeny of these crosses led to the conclusion that development does not 
appear to be significantly disrupted in the transgenic flies. When compared with the 
wild-type, both crosses show no extended wandering and larvae develop normally, 
progressing to the puparium stage. Transgenic flies with the MAC-NOS construct, 
however, appear to demonstrate increased lethality, with approximately half of the 
progeny not surviving past eclosion. 
General reduced Thor reporter staining is observed with little variation in the MAC-
NOS construct. Additionally, dFOXO
21
 and dFOXO
25
 mutants demonstrate different 
levels of Thor staining with less staining seen in dFOXO
25 
mutants. This is in contrast to 
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what would be expected as the two homozygotic lines both function as dFOXO null 
mutations and, consequently, should essentially display very similar levels of staining.  
Further investigation into the relationship between NO signalling via dFOXO was 
conducted by examining the effect that NOS2 expression had on Thor expression in the 
salivary glands. When expressed with a functional dFOXO copy, NOS2 expressing 
larvae have salivary glands that are reduced in size and increased Thor-LacZ staining. 
This phenotype and Thor staining levels do not occur in dFOXO
25
 homozygotes, 
showing complete suppression of these NOS2 induced phenotypes, but are incompletely 
suppressed in dFOXO
21
homozygotes. This difference in suppression is significant and 
implies that the mutations in both alleles have different effects that influence the 
strength of the dFOXO mutation. This effect might be due their different locations with 
the mutations generating stop codons at marginally different positions which could 
account for the different levels of suppression documented in Kimber (2005).  
Given that Kimber (2005) conducted these experiments on whole salivary glands, Scott 
(2009) opted to observe the effects of NO signalling on dFOXO in single cells located 
in the salivary glands during the third instar. Scott (2009) reported that the nuclear to 
cytoplasmic ratio of dFOXO protein expression in a UAS-NOS2 background is 
statistically significantly different compared with the wild type, with dFOXO nuclear 
expression being higher than levels in the cytoplasm. This analysis was conducted in 
whole salivary glands and UAS-NOS2-expressing clones. However, dFOXO protein 
levels are increased in comparison to the wild type in both analyses.  
4.1.9. dFOXO
21  
and dFOXO
25
: effective null mutations of dFOXO 
The variation between two mutations used in Drosophila (dFOXO
21
 and dFOXO
25
) is 
illustrated below in a comparison between the structure of dFOXO, human FOXO and 
DAF-16 forkhead domains: 
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Fig.4.1. Multiple sequence alignment indicating point mutations in dFOXO 
mutants 
Fig. 4.1. This multiple sequence alignment highlights that the forkhead domain is significantly 
conserved across the three species in both primary and secondary structure (shown above the 
sequence). Most relevant to this experiment are the two EMS-induced point mutations shown 
here in red. The colour coding of the amino acids residues reflects similarities and differences in 
primary structure. Grey and black show similar and identical sequences respectively (adapted 
from Junger et al., 2003). 
4.1.10. dFOXO
BG01018: a ‘mild’ dFOXO mutant 
When conducting a genetic screen for Drosophila mutants that differ in lifespan when 
infected with M. marinum compared with the wild type, Dionne et al. (2006) identified 
a specific long-lived mutant, dFOXO
BG01018
. The mutant has a transposon insertion 
termed BG01018 which is located approximately 130 nucleotides upstream of the 
FOXO start codon. Significantly, the effect of this mutation when compared with the 
other dFOXO alleles is characterised as mild (Dionne et al., 2006).  
4.1.11. dFOXO
21, 25 and BG01018
 in immunity 
As previously stated, research has shown that FOXO has documented roles in the 
immune system. Dionne et al. (2006) characterised the role of FOXO in M. marinum 
infected Drosophila while examining the metabolic consequences of this infection. M. 
marinum is closely related to M. tuberculosis which causes tuberculosis (Tønjum et al., 
1998). M. marinum itself causes lethal tuberculosis-like symptoms in Drosophila. 
Dionne et al. (2006) compared the lifespan of M. marinum infected wild-type and 
FOXO null mutants (dFOXO
21
, dFOXO
25
 and dFOXO
BG01018
). The FOXO mutant 
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animals all have a longer lifespan relative to the wild-type, which is an interesting 
discovery in itself; however, the three groups differ between themselves in terms of 
lifespan. The heterozygotes containing the dFOXO
BG01018
  allele have the least increase 
in lifespan while flies heterozygous for  dFOXO
21
 and dFOXO
25
 alleles survive longer. 
Studies suggest that differences observed in these mutations might be a result of the 
different sequences of each of their stop codons (Jünger et al., 2003; Kimber, 2005). 
A previous study conducted within our lab reveals some findings that point to the 
relationship between dFOXO and NO. It is shown that NO is dependent on dFOXO for 
its inhibitory effect on growth; this is explained further in the NO section of the 
introduction. However, it is also essential to add that in the same study it is also found 
that NO acts on dFOXO, ultimately promoting growth retardation within cells (Kimber 
et al.). 
4.1.12. NO growth inhibition is FOXO-dependent as previously demonstrated in 
laboratory 
Previous research conducted in our lab from Kimber et al. demonstrated that NOS-
induced growth regulation via NO signalling is dependent on the presence of dFOXO. 
Using larval salivary gland cells as a model, this was determined by silencing dFOXO 
through RNAi, which completely eliminates the growth inhibition produced by 
upregulated NO expression. Furthermore, NO signalling increases dFOXO expression 
which in turn upregulates d4E-BP transcription, resulting in growth inhibition as 
previously mentioned. This growth inhibition, however, can occur independently of 
d4E-BP.  
Kimber (2005) demonstrated that FOXO and NO share seven transcriptional targets and 
function to regulate their expression (Table.4.1). As a result the expression levels of 
some of these targets are reduced in response to NO and insulin signalling. Alternative 
responses to signalling can also be seen in the FOXO targets: Pepck and Thor, for 
example, which both demonstrate increased and decreased expression levels via NO and 
insulin signalling respectively. These results suggest that Pepck and Thor expression 
could be controlled through FOXO action influenced by NO signalling.  
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Table.4.1. A summary of transcripts measured in Drosophila S2 tissue culture cells, 
which are shown to be dFOXO targets through microarray analysis. Transcripts contain 
forkhead-response elements (FHREs) and are negatively regulated via insulin signalling 
(Kimber, 2005).  
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141780_at Cyp9c1 Cytochrome P450 4.1 1 0.73 1.04 0.16 1.18 0.34 1.11 
143299_at Pepck 4.6 1 0.08 1.86 0.23 2.82 0.02 2.62 
151885_at Long-chain-fatty-acid-CoA-Ligase 2.7 1 0.75 -1.05 0.62 1.07 0.13 -1.75 
153081_at Phosphorylase Kinase Gamma 2.4 1 0.4 -1.14 0.5 1.1 0.93 1.01 
153432_at Thor 3.3 1 0.23 2.86 0.26 8.16 0.05 5.95 
154078_at Cyp4e2 Cytochrome P450 2.9 1 0.41 1.27 0.12 1.89 0.04 1.91 
154586_at 
CPTI (mitochondrial 
carnitine palmitoyltransferase) 
4.5 1 0.78 -1.09 0.67 -1.17 0.25 -1.58 
 
 
In Kimber et al. NOS is shown to increase the expression of both dFOXO and d4E-BP, 
which results in growth inhibition. However, this growth inhibition and upregulated 
d4E-BP expression is FOXO-dependent, while growth inhibition via NO signalling is 
not d4E-BP-dependent. NO regulation of d4E-BP is analysed here through microarray 
analysis of the tissue culture cells and also by measuring d4E-BP-LacZ transcript and 
protein levels in transgenic flies. Additionally, the study has shown that overexpression 
of dFOXO and NOS separately, results in similar reduced growth phenotypes.  
Scott (2009) targeted murine NOS2 expression in single salivary gland cells in order to 
analyse the effects of increasing NO expression locally. The salivary gland cells 
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exhibited growth inhibition. On the cellular level it was shown that NO is able to diffuse 
between cells, and trigger increased dFOXO protein levels in both adjacent wild-type 
cells and NO-expressing cells. As previously mentioned, NO has a very short half-life 
of a few seconds which explains the results seen here. NO was only able to signal to 
increase in dFOXO levels at a short-range, only affecting neighbouring cells. Antibody 
staining using anti-dFOXO also showed that increased dFOXO expression is localised 
both in the cytoplasm (1.7 fold increase) and nucleus (1.6 fold increase). 
When measuring the effects of NOS2 on d4E-BP signalling, Kimber et al. showed that 
NO increases d4E-BP expression. In order to verify that this was not a result of natural, 
physiological variation between the flies sampled, Scott (2009) targeted  NOS2 
expression to single cells and the promoter activity and protein expression levels of 
d4E-BP was compared with non-adjacent cells in the same salivary gland. These 
analytical methods show that d4E-BP increased 1.6 fold in both the targeted cells when 
compared with the wild-type, non-adjacent cells.  
In order to test whether NO-induced growth inhibition is dFOXO-dependent, Kimber et 
al. measured NOS2 in flies homozygous for the null allele dFOXO
25
. In this case, the 
flies were viable and growth normal, which supports the theory that the growth 
inhibition is dFOXO-dependent. Similarly, the dFOXO
25 
allele was used again when 
determining if dFOXO is required for increased d4E-BP expression via NO signalling. 
Kimber (2005) analysed d4E-BP expression in these mutants, while also expressing 
NOS2. The removal of dFOXO resulted in d4E-BP expression that was similar to the 
wild-type expression levels, highlighting that NO functions to increase d4E-BP in a 
dFOXO-dependent process.  
When investigating the effects of overexpressing NO and dFOXO separately, Kimber et 
al. measured nuclei taken from larval salivary glands. Overexpression of both of these 
genes resulted in reduced nuclear sizes. On average, the wild-type nuclei measure at 
21μm and was reduced to under 13μm in flies overexpressing NO and 8μm in those 
overexpressing dFOXO.  
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4.1.13. Analysis of nuclei sizes when dFOXO mutants and NOS2 are co-expressed 
This chapter investigates the effect on nuclear sizes when NOS2 is expressed in animals 
carrying the dFOXO alleles: dFOXO
21
, dFOXO
25 
and dFOXO
BG01018
. Using both trans-
heterozygous and homozygous genotypic combinations of the alleles, this study will 
compare the nuclear sizes and determine the levels of suppression induced by the 
different alleles.  
 
Given that NO expression in a wild type dFOXO background decreases growth, the 
strength of mutation examined in these alleles will be indicated by the nuclear sizes. 
The change in nuclear size when NOS2 is expressed in a dFOXO mutant animal 
compared to NOS2 expression in a wild type background reveals the strength of that 
dFOXO allele. Additionally, Kimber et al., Scott (2009) and this present study use 
nuclear size measurements in order to estimate growth within the salivary glands, but 
this present study tests three dFOXO alleles instead of overexpressed dFOXO. 
In order to investigate if overexpressed NO can inhibit salivary gland growth in 
different dFOXO backgrounds, the three alleles (dFOXO
21
, dFOXO
25
 and 
dFOXO
BG01018
) were each co-expressed in homozygous and trans-heterozygous 
combinations with UAS-NOS2. In the trans-heterozygous combinations of the alleles, 
the parental cross was constructed using females from the first line annotated and males 
from the second line; for example, in the dFOXO
21
/dFOXO
25 
line, females were taken 
from the dFOXO
21
 line and crossed with males from the dFOXO
25 
line. In lines 
dFOXO
25
/dFOXO
21
 and dFOXO
25
/dFOXO
BG01018
, this method of gender selection was 
also conducted. Wild type c147-GAL4/+ was used as a control line. A NOS2-only 
expressing line was also used as a reference. 20 female third instar larvae from each line 
were dissected for their salivary glands. The glands were prepared, stained with DAPI 
and mounted in Aquamount (see Materials and Methods chapter). Using Zeiss Axiophot 
microscopy 1050 nuclie from 132 salivary glands  were visualised and measured at 40x 
magnification.  
 
 
 
 
 
56 
 
4.2. Results 
4.2.1. Statistical analysis of salivary gland nuclei measured in the different lines visualised 
using DAPI staining 
The control line c147/+ had the largest average nuclei size, measuring 23.8 μm, while the 
smallest nuclei sizes were found in the UAS-NOS2/+;c147/+ line with an average of 10.0μm. 
The other averages were taken from nuclei of the trans-heterozygous and homozygous dFOXO 
mutants (dFOXO
21, 25and BG01018
) expressing NOS2. Out of these dFOXO mutants, the 
homozygous dFOXO
25
/dFOXO
25
 animals were the most similar to the wild-type nuclear size, 
with an average size of 22.3μm. The lowest of these were nuclei of trans-heterozygous 
dFOXO
21
/dFOXO
BG01018
 mutants with an average of 13.80μm. 
 
Fig.4.2. is a graph of the average salivary gland nuclei sizes measured from the animals of the 
genotypes shown. All the lines expressed NOS2 except for the wild type. Error bars represent 
standard deviation. 
WT (c147-GAL4/+), NOS2 (UAS-NOS2/+; c147-GAL4/+), NOS2 dFOXO
25
/dFOXO
25 
(UAS-
NOS2,UAS-GFP/+;c147/+;dFOXO
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/ dFOXO
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), NOS2 dFOXO
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/dFOXO
21
 (UAS-
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4.2.2. Ultrastructural visualisation of the salivary glands expressing NOS, dFOXO, 
Myc and Ras via TEM 
In order to observe any ultrastructural changes to the cells of the salivary glands 
resulting from the expression of NOS, dFOXO, Myc and Ras, preparations were 
observed using the TEM. Three types of cellular structures could be easily observed; 
these include: nuclei, chromosomes and secretory vesicles. Comparisons were made 
between animals expressing these genes as well as comparisons to wild type animals. 
All images were visualised at 1000x magnification. 
When compared with the yw control line, the NOS2-expressing animals produced cells 
that were reduced in size. Additionally, the nuclei and polytene chromosomes were also 
decreased in size, indicating reduced endoreplication. Secretory vesicles could not be 
observed, suggesting that they were absent in the cell. Therefore, NOS2-expressing 
cells had smaller nuclei and polytene chromosomes compared to wild types, and the 
secretory vesicles were not visible (Fig.4.4.). 
Expression of NOS2 in dFOXO
25/25 
homozygotes generated cellular structures similar to 
the wild type. Cellular structures visualised from glands extracted from these animals 
were almost identical to wild type proportions observed in the nuclei, polytene 
chromosomes and secretory vesicles (Fig.4.5.). 
Moreover, introducing NOS2 in dFOXO
25
/dFOXO
BG01018
 transheterozygotes generated 
smaller nuclei and chromosomes, but secretory vesicles were similar to wild type 
proportions. These animals also expressed NOS2 and displayed smaller nuclei and 
polytene chromosomes than the wild type and the dFOXO
25/25
 animals, indicating a 
decrease in endoreplication relative to these lines. Secretory vesicles appeared normal 
(Fig.4.6.).  
In addition, expression of NOS2 in dFOXO
BG01018
/dFOXO
BG01018 
homozygotes 
generated smaller nuclei and chromosomes, but secretory vesicles were quite similar in 
comparison to the wild type. Animals that expressed NOS2, and were homozygous for 
dFOXO
BG01018
, produced nuclei and chromosomes that appeared slightly smaller than 
the previously mentioned lines. Secretory vesicles remained normal (Fig.4.7.). 
Expression of NOS2 in dFOXO
25
/dFOXO
21
 transheterozygotes generated smaller 
nuclei, chromosomes and secretory vesicles. Salivary gland cells contained nuclei, 
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chromosomes and secretory vesicles that were all slightly reduced in size when 
compared with the previously mentioned lines (Fig.4.8.). 
Expressing NOS2 in dFOXO
21
/dFOXO
BG01018 
transheterozygotes generated small 
nuclei, chromosomes and secretory vesicles. This line had small nuclei, polytene 
chromosomes and secretory vesicles when compared with the wild type. It also had the 
smallest nuclei measurements on average when using DAPI staining (with the exception 
of the UAS-NOS2 line) (Fig.4.9.). 
Note that dFOXO
21
 homozygote animals did not survive to third instar larvae when 
expressing NOS2. Unfortunately, this prevented a direct comparison with all three of 
the dFOXO homozygotes. 
 
 
 
 
 
 
 
59 
 
Fig.4.3.Control Genotype (c147-GAL4/+): Wild type nuclei, polytene chromosomes and secretory 
vesicles. 
 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Fig.4.4.Overexpression of NOS2 (UAS-NOS2/+; c147-GAL4/+): Nuclei and polytene chromosomes 
from animals overexpressed NO are shown. 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Fig.4.5. UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
25
 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Fig.4.6.UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
BG01018 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Fig.4.7.UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
BG01018
/ dFOXO
BG01018
 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Fig.4.8.UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
21 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Fig.4.9. UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
21
/ dFOXO
BG01018 
*Yellow arrows (          ) identify polytene chromosomes inside the nucleus; red arrows (          ) 
indicate secretory vesicles. Scale bars 2μm. 
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Table 4.2.Comparative analysis of cellular ultrastructure observed in the different lines 
 
  
Table.4.2. This table compares the differences observed in cellular ultrastructure for each 
genotype. Wild type proportions were used as a control line and sample tissues were all third 
instar salivary glands. The homozygous dFOXO
25
 (expressing NOS2) animals were most 
similar to the wild type in cellular ultrastructural proportions. The dFOXO
21
/dFOXO
BG01018
 line 
(expressing NOS2) showed the least similarity when compared with the wild type, considering 
all three cellular structures (nuclei, polytene chromosomes and secretory vesicles) and were 
significantly reduced in cell size. 
 
 
 
 
 
 
 
 
 
Figure 
Reference Genotype 
NOS2 
Expression Nuclei Chromosomes 
Secretory 
Vesicles 
Fig.4.3. Control Genotype (c147-GAL4/+) No 
Wild type 
proportions 
Wild type 
proportions 
Wild type 
proportions 
Fig.4.4. 
Overexpression of NOS2 (UAS-NOS2/+; 
c147-GAL4/+) Yes 
Greatly 
decreased in 
size 
Greatly 
decreased in 
size 
Could not be 
observed 
Fig.4.5. 
UAS-NOS2,UAS-GFP/+;c147/+;dFOXO25/ 
dFOXO25 Yes 
Very similar 
to wild type 
Very similar to 
wild type 
Very similar 
to wild type 
Fig.4.6. 
UAS-NOS2,UAS-GFP/+;c147/+;dFOXO25/ 
dFOXOBG01018 Yes 
Decreased in 
size 
Decreased in 
size 
Similar to 
wild type 
Fig.4.7. 
UAS-NOS2,UAS-
GFP/+;c147/+;dFOXOBG01018/ dFOXOBG01018 Yes 
Decreased in 
size 
Decreased in 
size 
Similar to 
wild type 
Fig.4.8. 
UAS-NOS2,UAS-GFP/+;c147/+;dFOXO25/ 
dFOXO21 Yes 
Decreased in 
size 
Decreased in 
size 
Decreased in 
size 
Fig.4.9. 
UAS-NOS2,UAS-GFP/+;c147/+;dFOXO21/ 
dFOXOBG01018 Yes 
Strongly 
decreased in 
size 
Strongly 
decreased in 
size 
Strongly 
decreased in 
size 
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4.3. Discussion 
4.3.1. dFOXO
25
 is the strongest loss of function dFOXO allele in this experiment 
As the dFOXO mutant line with the largest average size of nuclei, measurements from 
the dFOXO
25
/dFOXO
25
 line expressing NOS2 suggested that NO signalling was more 
impaired when compared with the other dFOXO genotypes. This is supported  by 
Dionne et al. (2006) which described dFOXO
BG01018
 as a mild dFOXO null allele. When 
examining Thor reporter activity in dFOXO mutant backgrounds, Kimber (2005) 
reported that dFOXO
25
 homozygotes mutants showed more Thor LacZ staining than 
dFOXO
21 
homozygotes. However, the study is inconclusive as to why this variation 
might have occured. Since dFOXO is demonstrated to increase Thor expression (Jünger 
et al., 2003), a strong dFOXO mutation, such as homozygous dFOXO
25
 would decrease 
Thor expression more significantly than a weaker dFOXO mutation, such as 
homozygous dFOXO
21
.  
The three alleles appeared to demonstrate different strengths of dFOXO activity; as a 
result, NO-induced growth inhibition was muted at different levels. The difference in 
nuclear sizes between the three alleles when combined with NOS2 could be due to the 
variations in the positions of the stop codons as previously mentioned (Kimber, 2005) in 
the cases of dFOXO
21
 and dFOXO
25
. dFOXO
BG01018
 is characterised as a mild mutation 
containing a transposon insertion upstream of the dFOXO gene (Dionne et al., 2006); 
therefore, dFOXO transcription is decreased as a consequence of this insertion which 
reduces dFOXO function to a lesser extent than dFOXO
25
. However, the results from 
this experiment suggest that dFOXO
BG01018 
may have a stronger deleterious effect on 
dFOXO activity than the dFOXO
21
 allele. 
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4.3.2. Using TEM to visualise the ultrastructure of salivary gland cells 
When salivary glands from all three dFOXO mutant lines were analysed using TEM, 
alterations to cellular structures such as nuclei, chromosomes and secretory vesicles 
mostly correlated with changes to the nuclei measurements. When compared with the 
control line, the ultrastructure visualised in dFOXO
25
/dFOXO
25
 animals showed the 
highest degree of similarity to the wild type.   
TEM is generally considered a poor indicator of size in cells given that the sections are 
100nm thick and the structures measured are several times thicker. However, 
aberrations in cellular structure and the presence of different organelles can be 
visualised using TEM, validating its use here. This project reports that no aberrations in 
organelles’ structures were documented here, although the NOS2 expressing salivary 
gland cells did not contain any secretory vesicles. There is currently no evidence to 
explain the disappearance of the secretory vesicles in the available literature. The results 
seen in this Chapter suggest that NOS2 acts to impair the formation of these structures.  
To conclude, this Chapter has identified the dFOXO
25
 allele as the strongest reduction 
in dFOXO activity of the three dFOXO mutant alleles discussed here. Futhermore, the 
dFOXO
21
/dFOXO
BG01018 
mutants have the weakest impairment of dFOXO activity. This 
analysis of the different strengths of dFOXO mutation was determined by measuring 
nuclear sizes taken from each line and also using TEM to observe cellular ultrastructure. 
In addition, this study demonstrates that the inhibition of both growth and secretory 
vesicle formation by NO can both be suppressed by inhibition of dFOXO activity. 
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Chapter 5 
 
Investigating The Effects of Nitric Oxide on the Mitochondria 
and Golgi of Salivary Glands 
 
5.1. Introduction 
5.1.1. Mitochondria  
Mitochondria are present in significant numbers in metabolically active cells and can 
account for approximately 40% of volume in the cytoplasm. Their numbers can range 
from the hundreds to the thousands in cells from organs such as the kidneys, liver and 
brain. While metabolically-inactive organs such as the skin contain far fewer 
mitochondria, studies indicate that an adult human might have as much as 10% of their 
body weight attributed to the mass from mitochondria with the entire body containing 
approximately 10 million billion mitochondria at a given time (Nisoli and Carruba, 
2006).  
In addition to the scale of their numbers, mitochondrial function in cellular respiration 
has fascinated biologists for half a century. More recently, it has been discovered that 
these organelles never experience stasis. They are always in motion, undergoing fission 
and fusion within cells, events which lead to changes in numbers, mass and the size of 
mitochondria (Meeusen et al., 2004; Okamoto and Shaw, 2005). This constant, dynamic 
activity is regulated by differentiation states and different stimuli. 
The role of mitochondria in energy production is crucial to the theories of the original 
development of complex eukaryotes. Additionally, this function is attributed to diseases 
associated with aging, cell death and birth (Harman, 1972).  
5.1.2. Mitochondrial NOS is a posttranslationally-modifed form of nNOS 
Bates et al., (1995) was the first study to report the presence of nitric oxide in 
mitochondria, mitochondrial NOS (mtNOS), via immunocytochemistry in the rat brain 
and liver mitochondria. Following this discovery several studies demonstrated the 
characteristics of this NOS isoform which include: localisation to the inner 
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mitochondrial membrane and Ca
2+
 dependency (Giulivi et al., 1998; Carreras et al., 
2001; Ghafourifar and Cadenas, 2005). 
In order to understand how mtNOS is regulated and expressed relative to the other NOS 
isoforms, Elfering et al. (2002) attempted to identify the chemical composition of 
mtNOS through several techniques. Using amino acid analysis, mass spectrometry of 
proteolytic fragments, PCR analysis and molecular weight, the study identified mtNOS 
as nNOSα, eliminating the possibility of a novel isoform. mtNOS differs from nNOS by 
two posttranscriptional modifications: myristoylation at the N-terminal and 
phosphorylation of the C-terminal, alterations which may confer enhanced membrane 
binding and enzymatic regulation respectively (Elfering et al., 2002).  
5.1.3. Role of NO in regulating mitochondrial function 
The function of NO as a vasodilator regulates mitochondrial function. Vasodilation is 
characterised by blood being directed to tissues; therefore, it presents additional 
substrates for mitochondria involved with cellular respiration and indirectly aids in 
spreading heat generated by actively respiring mitochondria. O2 is also supplied to 
mitochondria for energy production via the action of NO in releasing O2 from 
haemoglobin (Woltz et al., 1999).  
NO can compete with O2 in the electron-transport chain by binding to the terminal 
protein in the chain, cytochrome c oxidase. The function of this terminal enzyme is 
disrupted through NO binding and serves to negatively regulate oxidative 
phosphorylation that would otherwise occur through binding with O2 (Brown and 
Cooper, 1994; Clementi et al., 1998).  
Mitochondrial activity is essential for processes such as the glycolytic to oxidative 
metabolism conversion seen in skeletal muscle fibres (Lin et al., 2002). Furthermore, 
mitochondria are involved in skeletal and cardiac muscle regeneration (Lehman et al., 
2000; Stamler and Meissner, 2001).  
Studies with eNOS null mutations indicate that mice require eNOS for mitochondrial 
biogenesis, identifying NO as a crucial biogenetic stimulus. Pathology associated with 
mitochondrial dysfunction includes neurodegenerative diseases, diabetes (type II), liver 
and heart failure, and neuromuscular disorders (Lehman et al., 2000; Patti et al., 2003; 
Mootha et al., 2003).  
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5.1.4. eNOS mutants inhibit mitochondrial activity in obesity and diabetes 
Obesity and diabetes stand out as two pathological conditions that are especially 
influenced by eNOS null mutations. eNOS
-/-
 mice that consume the same amount of 
food as the wild type reference gain and retain more weight. This is likely a result of 
defective energy expenditure (Nisoli et al., 2003). Additionally, this is supported as 
these mutant mice display low O2 consumption which demonstrates decreased 
metabolic activity. Therefore, this underlines the importance of functional eNOS in 
mitochondrial action. The study undertook  an in vitro experiment by introducing the 
NO donor, SNAP, to HeLa, 3T3-L1 and U937 cells,  and to brown adipocytes and 
concluded that NO triggers mitochondrial biogenesis in these cells. This process is 
dependent on guanosine 3’, 5’- monophosphate (cGMP) and induces peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC-1α), which is known to promote 
mitochondrial biogenesis (Nisoli et al., 2003). 
Effective treatment for such impaired energy expenditure could possibly include 
generating functional mitochondria to increase energy expenditure which would in turn 
decrease obesity and the likelihood of generating diabetes. However, some studies 
suggest a relationship between cell dysfunction and mitochondrial biogenesis induced 
by NO (Carew et al., 2004; Nagy et al., 2004). 
Mitochondrial biogenesis through NO action may therefore be involved in regulating 
metabolism and signal transduction. These organelles are crucial for maintaining cell 
function and survival, and signalling compounds that regulate their production should 
be carefully investigated. 
5.1.5. dFOXO regulates mitochondrial biogenesis via Spargel inhibition 
In order to examine the mechanism by which nutrition induces transcriptional 
modifications, Gersham et al. (2007) compared feeding-induced transcriptional changes 
with dFOXO targets. Remarkably, dFOXO regulated 28% of the genes that respond to 
feeding. These included genes which are associated with mitochondrial biogenesis, such 
as a Drosophila orthologue of mammalian PGC-1, CG9809, which codes for the 
protein, Spargel.  
In mammals, activation of PGC-1 is reported to increase mitochondrial gene expression 
and is a ‘master regulator of mitochondrial biogenesis’ (Nisoli et al., 2003). Spargel is 
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made up of 1088 amino acids and exhibits 68% similarity with PGC-1 in the COOH-
terminal motif that binds to RNA. Interestingly, Tiefenbock et al. (2010) reported that 
“Spargel is not a master regulator of mitochondrial biogenesis”. 
In contrast to the greatly increased mitochondrial biogenesis produced by PGC-1 
expression, ectopic expression of Spargel does not increase mitochondrial abundance 
(Tiefenbock et al., 2010). Gersham et al. (2007) reported that dFOXO is a vital 
regulator of the feeding-induced transcriptional response downstream of insulin and 
suggests that dFOXO mediates repression of Spargel in the insulin signalling pathway 
which is linked to mitochondrial biogenesis. Therefore, the effects of overexpressed 
dFOXO on mitochondrial biogenesis in the experiment conducted in this paper will be 
interesting to note as they may reflect repression of Spargel by dFOXO. 
5.1.6. dMyc regulates mitochondrial biogenesis structure and function 
In order to investigate dMyc targets, Orian et al. (2003) utilised the DamID technique to 
map dMyc targets in the Drosophila genome. This study demonstrated that dMyc binds 
to six genes associated with mitochondrial biogenesis, function and structure (CG3476, 
mge, mRpL10, mRpS7, TFAM and Tim10). Expanding upon this research, Li et al. 
(2005) examined the role of Myc in regulating mitochondrial biogenesis. Ectopic Myc 
was expressed in P493-6 rat cells and increased mitochondrial growth and function was 
observed. Furthermore, Myc null alleles were generated in rat fibroblast cells which 
resulted in decreased mitochondrial mass and number of normal mitochondria. The 
ability of Myc to rescue this null allelic condition was tested by reintroducing Myc into 
the fibroblasts. Mitochondrial mass and function were almost completely restored and 
mitochondria appeared normal. These results support the evidence described in the 
previous study and demonstrate that Myc is a vital regulator of mitochondrial 
biogenesis, structure and function.   
Larval Drosophila cells overexpressing dMyc show increased endoreplication which 
reflects increased growth. By staining Drosophila embryos with MitoTracker red which 
measures mitochondrial activity, Frei et al. (2005) observed that mitochondrial activity 
is unaffected by overexpressed dMyc. Thus, dMyc can stimulate growth without 
increased levels of ATP which is unexpected since one would normally predict that 
mitochondrial activity and energy production would be elevated along with increased 
growth. 
 
 
73 
 
 
5.1.7. Ras and Mitochondria 
The Ras isoform, Kirsten Ras (K-Ras), has been linked to human cancer (Bos, 1989) 
and differs from the other isoforms by its membrane-binding sequence. Mutated K-Ras 
is implicated in 90% of human pancreatic cancers, for example (Almoguera et al., 
1988). Inactive K-Ras is normally associated with the plasma membrane via 
farnesylation. It has a polybasic sequence which can be phosphorylated by protein 
kinase C (PKC). Biovona et al. (2006) showed that PKC can regulate the function and 
location of K-Ras. Once K-Ras is phosphorylated, it disassociates from the plasma 
membrane and associates with numerous intracellular membranes. The outer 
mitochondrial membrane is included among these membranes with which K-Ras has 
been found to associate. Specifically, K-Ras binds with the mitochondrial 
transmembrane molecule, Bcl-XL, a member of the Bcl family that regulates autophagy 
and apoptosis. Phospho-K-Ras then upregulates apoptosis via Bcl-XL. This association 
between activated K-Ras and apoptosis might at first appear contradictory since Ras is 
well documented to induce cell growth and survival. However, Ras and its various 
isoforms are also known to be associated with proapoptotic processes (Cox and Der, 
2003).   
 
5.1.8. Golgi 
First discovered by Camillo Golgi in 1898, the Golgi had been the subject of dispute as 
it was first thought to be an artefact. Its roles in packaging and transporting proteins are 
well-documented. Proteins can be trafficked to and from the Golgi via vesicular 
transport. The Golgi is also involved in: secretion granules packaging, glycosylation of 
glycoproteins and glycolipids on the posttranslational level via glycolysation, sulfation, 
proteolytic processing of proproteins, packaging lipoprotein and multi-directional 
trafficking of molecules (Farquhar and Palade, 1981). This study analysed the 
relationships between Golgi and growth regulators NO and FOXO, in addition to 
oncogenes Ras and Myc. 
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5.1.9. Localisation of eNOS on the Golgi is required for NO production in the 
endothelial cells 
In endothelial cells, NO is generated by eNOS and functions to maintain vascular tone 
and contribute to angiogenesis (Papapetropoulos et al., 1997). Sessa et al. (1995) 
characterised its localisation in endothelial cells and blood vessels as a protein 
associated with the Golgi complex and plasma membrane. In order for eNOS to 
efficiently produce NO it must be activated by signalling processes, specifically, Akt-
dependent phosphorylation by vascular endothelial growth factor (VEGF).  Fulton et al. 
(2002) demonstrated that this phosphorylation occurs on serine 1179 of eNOS; the 
study investigated this interaction by cotransfecting eNOS and Akt into endothelial cells 
and stimulating these cells with VEGF. This raised the levels of phosphorylated eNOS 
(P-eNOS) within the cell relative to total eNOS, but did not change the distribution of 
these enzymes. These results indicate that phosphorylation and activation of eNOS via 
Akt and VEGF signalling are critical to produce NO, since an increase in P-eNOS 
means that more eNOS is activated and produces more NO. 
The association between eNOS and the Golgi apparatus and plasma membrane must be 
correctly localised in order for the agonist VGEF to contribute to optimal NO 
production (Fulton et al., 2002). The requirement of proper localisation is verified by 
transfecting endothelial cells with a modified form of eNOS which is mistargeted. 
VGEF stimulation did not increase P-eNOS in this case, signifying that NO production 
does not increase if eNOS is not localised in the Golgi complex or plasma membrane.  
5.1.10. PKBi sequestration in the Golgi regulates FOXO localisation and function 
Current literature available does not describe any potential binding, post-translational 
modification or transport occurring between FOXO and the Golgi apparatus. However, 
the Golgi apparatus can indirectly affect FOXO localisation and function as a 
transcription factor by sequestering PKB/Akt inhibitors (PKBis). Maiuri et al. (2010) 
restricted these inhibitors to the Golgi apparatus to elucidate the context-specific 
physiological outcomes associated with the mechanisms involved in the PKB/Akt 
pathway, which is comparable to creating gene knockouts with the purpose of 
examining their function. Since this pathway functions to phosphorylate FOXO, 
preventing it from localising in the nucleus and regulating transcription (Brunet et al., 
1999), PKBis can in turn inhibit FOXO sequestration in the cytoplasm through 
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PKB/Akt pathway inhibition. Maiuri et al. (2010) confirmed this action by reporting 
that PKBis sequestration to the Golgi apparatus hinders its ability to inhibit the 
PKB/Akt pathway, thus resulting in FOXO localisation in the cytoplasm. 
5.1.11. Modification of the CAAX motif targets Ras to the Golgi  
Ras proteins are targeted from the cytoplasm to the plasma membrane via 
posttranslational modification at the C-terminal CAAX motif (Clarke, 1992). A series of 
enzymes bind this structural motif sequentially, modifying the terminal in order to target 
it to the plasma membrane (Reiss et al., 1990). Additional studies indicate that these 
enzymes are localised in the endomembrane system (Dai et al., 1998; Romano et al., 
1998; Schmidt et al., 1998). This localisation suggests that Ras travels to the 
cytoplasmic face of the endomembrane system prior to visiting the plasma membrane.  
Choy et al. (1999) investigated this theory by tagging a catalogue of CAAX proteins 
(including Ras) with GFP. Using high-resolution digital epifluorescence microscopy to 
determine the localisation of these proteins, the study demonstrated that Ras is 
expressed in the Golgi and peri-Golgi vesicles before localising to the plasma 
membrane. Thus far, three Ras isoforms, neuroblastoma- (N-) Harvey- (H) and K-Ras-
4A are documented to transit to the Golgi (Karnoub and Weinberg, 2008).  
Choy et al. (1999) determined that prenylation via two prenyltransferases is the only 
posttranslational modification to the CAAX motif that is required for association with 
the Golgi, while further modifications are required for association with the plasma 
membrane. Furthermore, the three Ras proteins are also known to traffic to the Golgi 
from the plasma membrane in a retrograde manner following additional chemical 
modifications (Rocks et al., 2005; Fivaz and Meyer, 2005); this bi-directional, recycling 
mechanism for Ras proteins suggests a regulatory role in signalling (Rocks et al., 2005).  
In T lymphocytes, PLCγ and RasGRP1 are demonstrated to mediate Ras activation on 
the Golgi. This differs from Ras activation on the plasma membrane which is mediated 
by the Grb2/SOS pathway (Mor and Philips, 2006). Activation in compartmentalised 
signalling is thought to serve the purpose of increasing the signal complexity of Ras; 
however, further investigation is required in order to determine if this type of signalling 
produces differential signalling outputs. Research suggests that Golgi is coupled to N-
Ras signalling because this isoform is the most abundant of the three associated with the 
Golgi (Omerovic and Prior, 2009).   
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The available literature does not contain any evidence of chemical interaction and/or 
localisation between Myc and Golgi. Therefore, for the purposes of this experiment, this 
paper assumes that there are none.  
This chapter discusses an experiment used in this study aimed at investigating possible 
effects of FOXO, NOS2, Myc and Ras overexpression on expression of mitochondria 
and golgi. By investigating the expression of mitochondria and Golgi in these different 
genetic backgrounds, any effects of these growth regulators on the expression of these 
intracellular compartments can be observed.  
This experiment uses mitoYFP and GolgiYFP tagging to observe the expression of 
mitochondria and Golgi in third instar salivary glands, which can give an approximation 
of the number of these two organelles. Although mitochondria and Golgi are too small 
to observe changes in their size in this experiment, these parameter in the larger salivary 
gland cells will be discussed.  
5.1.12. YFP constructs 
Green fluorescent protein (GFP) was first discovered in the jellyfish Aequorea Victoria 
and has since been often used as a reporter of gene expression. As a reporter it is useful 
in biological applications because once mature it is highly stable in many diverse 
environments and its spectrum can also be manipulated by mutagenesis. However, 
maturation of GFP is inefficient at 37°C, restricting its use in some experimental 
designs and prompting researchers to find alternatives. Yellow fluorescent protein 
(YFP) is one such variant and is often preferred given that it has displayed an improved 
maturation rate, produces increased brightness, and is less dependent on constant pH 
and halide levels (Rekas et al., 2002).  
LaJeunesse et al. (2004) described two different transgenes specific for Drosophila that 
ubiquitously expressed enhanced YFP (EYFP) targeted to intracellular membrane-
bound compartments: the Golgi and mitochondria. In these constructs, the moieties 
targeted to each type of membrane protein were amplified using PCR from expression 
vectors found in mammals and were subsequently cloned into a Drosophila spaghetti 
squash (sqh) CASPER 4 P-element transformation vector (La Jeunesse et al., 2004). 
The sqh promoter is ubiquitously expressed, allowing the study to examine expression 
of these constructs in several tissues. Given that these expression vectors were derived 
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from mammals, LaJeunesse et al. (2004) sought to observe these constructs in 
Drosophila in order to verify that this method was viable. Salivary glands from third 
instar larvae expressing these constructs were preferentially examined given the ease of 
visualisation of these relatively large cells and demonstrated successful uptake of the 
EYFP constructs and their moieties shown below in Fig.5.1. 
Fig.5.1. Drosophila sqh was utilised to enhance the expression of the mammalian expression 
vectors pEYFP-Golgi and pEYFP-Mito for Golgi and mitochondria, respectively, in Drosophila. 
UTR – untranslated region. SV40 – simian virus 40. indicates transcription initiation (taken 
from LaJeunesse et al., 2004).   
 
The constructs for mitoYFP and GolgiYFP used in this experiment were obtained from 
the Bloomington and are identical to those described in LaJeunesse et al. (2004). P{sqh-
EYFP-Mito}3 and P{sqh-EYFP-Golgi}3 are homozygous viable and fertile, third 
chromosome insertions (Flybase). 
 
5.2. Results   
Lines that contained mitoYFP and GolgiYFP constructs were crossed with lines 
expressing FOXO, NOS2, Myc and Ras. Additionally, these two constructs were 
crossed with yellow white (YW) lines in order to establish viability in a wild type 
genetic background. Salivary glands were extracted from lines expressing the two 
constructs, and the progeny of these crosses. These glands were mounted on slides and 
were visualised using confocal microscopy. All images were viewed at 63X objective 
(high power). In each image, the green fluorescence indicates YFP reporter activity. 
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When compared with the control line (Fig.5.2.), the line expressing NOS2 and the 
mitoYFP construct showed decreased salivary gland cell growth. Additionally, more 
mitoYFP reporter activity could be seen in the NOS2 expressing animals, indicating that 
overexpressed NO may have increased mitochondrial biogenesis (Fig.5.3.). 
Animals that overexpressed dFOXO and possessed the mitoYFP construct showed 
increased mitoYFP reporter activity in the line. Salivary glands were even smaller than 
lines expressing NOS2 (Fig.5.4). 
As shown in Fig.5.4. Myc increased mitoYFP reporter activity when compared with the 
control line. This indicated an increase in mitochondrial expression. The combination of 
Myc and mitoYFP expression also generated larger salivary gland cells (Fig.5.5.). 
The line expressing Ras
V12
 and mitoYFP generated larger salivary glands. However, 
mitoYFP reporter activity was not abundant and was more comparable with the control 
line. This suggests that this genotype did not increase mitochondrial expression 
(Figs.5.6). 
In animals that expressed Golgi YFP in a NOS2 background no major changes were 
observed other than a reduction in salivary glands sizes from NO growth inhibition 
(Fig.5.8.). 
FOXO overexpression in another line  resulted in growth inhibition, producing smaller 
salivary glands when compared with the wild type, but no significant alterations in 
GolgiYFP staining were observed (Fig.5.9.). 
Animals expressing the GolgiYFP construct and Ras
V12 
exhibited larger salivary glands. 
In addition, GolgiYFP reporter activity was comparable with the control line 
(Fig.5.10.). 
The line expressing the GolgiYFP construct line and Myc demonstrated a general 
increase in salivary gland size when compared with the wild type. Furthermore, 
GolgiYFP reporter expression did not appear to be significantly different (Fig.5.11).  
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 Fig.5.2. c147-Gal4/+; p{w[+mC]=sqh-EYFP-Mito}3/+ (control line) 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
 
 
 
 
 
   Fig.5.3. NOS2 /+; c147-Gal4/+; p{w[+mC]=sqh-EYFP-Mito}3/+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm.  
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Fig.5.4. c147-Gal4 /UAS-FOXO; p{w[+mC]=sqh-EYFP-Mito}3/+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
 
 
 
 
 
 
 
 
Fig.5.5. c147-Gal4/+; p{w[+mC]=sqh-EYFP-Mito}3/UAS-Myc 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
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Fig.5.6. c147-Gal4/UAS-Ras
V12
; p{w[+mC]=sqh-EYFP-Mito}3/+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
  
 
 
 
 
 
 
 
 
Fig.5.7. c147-Gal4/+; p{w[+mC]=sqh-EYFP-Golgi}3/+ (control line) 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
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Fig.5.8. NOS2 /+; p{w[+mC]=sqh-EYFP-Golgi}3 /+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
 
  
 
 
 
 
 
Fig.5.9. c147-Gal4 /UAS-FOXO; p{w[+mC]=sqh-EYFP-Golgi}3 /+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
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Fig.5.10. c147-Gal4/UAS-Ras
V12
; p{w[+mC]=sqh-EYFP-Golgi}3 /+ 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm.  
 
  
 
 
 
Fig.5.11. c147-Gal4/+; p{w[+mC]=sqh-EYFP-Golgi}3 /UAS-Myc 
*Yellow arrows (         ) identify expression of mitoYFP. Scale bars 10μm. 
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5.3. Discussion 
 
5.3.1. NO may increases mitochondrial biogenesis 
The results for animals expressing NOS2 showed that the intensity of mitoYFP staining 
increased, indicating that the number of mitochondria increased (Figs 5.3.). eNOS has been 
demonstrated to regulate mitochondrial biogenesis as demonstrated by decreased biogenesis 
in eNOS null mutations in mice (Nisoli et al., 2003). Nisoli et al. (2003) reported that the NO 
donor SNAP can induce mitochondrial biogenesis in a variety of cells, in a cGMP-dependent 
mechanism to induce PGC-1 which is a primary regulator of mitochondrial biogenesis. 
Therefore, the increase in mitoYFP expression indicates that mitochondria biogenesis in 
Drosophila salivary gland cells can also respond to increased levels of NO. This response 
may also be in a cGMP-dependent manner.  
5.3.2. dFOXO may mediates mitochondrial biogenesis 
 dFOXO overexpression also acted to increase mitoYFP reporter activity, which implies that 
dFOXO also acts to increase mitochondrial biogenesis. This conclusion is supported by 
Gersham et al. (2007), which argued that the insulin signalling pathway and mitochondrial 
biogenesis are linked. The study concluded that dFOXO-mediated repression of Spargel 
drives mitochondrial biogenesis. Although the mammalian homologue of Spargel can 
increase mitochondrial biogenesis, Spargel does not exhibit this function in Drosophila 
(Tiefenbӧck et al., 2010). The study also noted that Spargel mutants surprisingly do not 
demonstrate reduced mitochondrial biogenesis in contrast to the mammalian isoform. 
Tiefenbӧck et al. (2010) argued that Spargel repression via dFOXO overexpression is 
responsible for generating the abundant mitochondrial expression. Additionally, since SNAP-
induced activation of PGC-1 also acts to generate mitochondrial biogenesis (Nisoli et al., 
2003) and NO is demonstrated to signal through dFOXO to control growth and proliferation 
as shown in this Chapter and Kimber (2005), it also possible that NO signals through dFOXO 
in order to increase mitochondrial biogenesis. 
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5.3.3. dMyc may increases mitochondrial biogenesis 
Fig.5.5. indicates that overexpression of dMyc increased salivary gland size as well as 
biogenesis of mitochondria. Abundant mitoYFP reporter activity demonstrated here can be 
explained by several studies. Orian et al. (2003) conducted a global genomic mapping 
analysis of dMyc in Drosophila using the DamID method and identified six dMyc targets 
(Tim10, mRpL10, mRps7, mge, CG3476 and TFAM) associated with mitochondrial function, 
structure and biogenesis. This demonstrates that dMyc has a regulatory role in mitochondria 
regarding these components. 
Subsquently, Li et al. (2005) used ectopic expression of Myc in rat P493-6 cells to observe 
the effects on mitochondria. These cells showed an increase in mitochondrial function and 
mass, as well as oxygen consumption relative to the wild type. In contrast, Myc null rat 
fibroblasts showed a decrease in mitochondria numbers and mass. The study demonstrated 
the ability of Myc to partially rescue this phenotype suggesting that the oncogene has a 
crucial role in mitochondrial biogenesis. However, this role does not extend to mitochondrial 
activity, as dMyc overexpression has no effect on this characteristic (Frei et al., 2005).  
These studies account for the increased biogenesis demonstrated in this project, suggesting 
that dMyc overexpression can drive mitochondrial biogenesis in salivary glands. 
5.3.4. Ras
V12 
may not affect expression/biogenesis of mitochondria 
As shown in Fig. 5.6. salivary gland cells expressing Ras
V12 
showed an increase in salivary 
gland cell size; however, there did not appear to be an effect on mitochondrial expression 
when compared with the wild type. This is reflected in the available literature in which there 
are few studies describing links between Ras and mitochondria. Biovona et al. (2006) 
reported that the Ras isoform, K-Ras, can be activated by PKC and then subsequently 
associate with several organelles, including mitochondria. The mitochondrial transmembrane 
molecule, Bcl-XL, is a K-Ras target and the study found that Phospho-K-Ras upregulated 
apoptosis via Bcl-XL. This observation does not relate to the phenotype demonstrated here, as 
the cells appeared normal despite the increase in size. 
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5.3.5. NOS2, dFOXO, Ras
V12
 and dMyc might not regulate Golgi expression 
The growth regulators used do not alter Golgi expression and only seem to affect the size of 
the salivary gland cells. Predictably, oncogenes dMyc and Ras
V12 
showed a general increase 
of salivary gland cell size, also generating larger nuclei relative to the wild type. Growth 
inhibitors, dFOXO and NOS2 produced decreased salivary gland cells and also smaller 
nuclei. However, none of these regulators had an impact on Golgi expression which is 
supported by the absence of studies documenting any effect on Golgi expression when 
examining the available literature. 
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                                              Chapter 6 
                                             Discussion 
6.1. Introduction 
Using the model system Drosophila, this thesis demonstrates that the dFOXO
25
 homozygotes 
gave the most suppression of NOS2-induced under-proliferation when compared with 
dFOXO
21
 and dFOXO
BG01018
. Additionally, when NOS2 was co-expressed with Ras and Myc, 
aberrations in ER ultrastructure were visualised. It is suggested that these oncogenes and 
NOS2 combine to produce peroxynitrite which could explain this phenotype. Furthermore, 
this thesis argues that overexpression of Myc, dFOXO and NO can induce mitochondrial 
biogenesis. 
 
6.1.1. NOS2 expression removes the salivary gland secretory vesicles 
When TEM was used to visualise the ultrastructure of salivary glands in NOS2 expressing 
cells, secretory vesicles were not observed. The available literature does not document any 
previous interaction between nitric oxide and secretory vesicles, even in other organisms. It is 
interesting to note that this phenotype is also suppressed by inhibition of dFOXO activity.  
 
6.2.Co-expressing NOS2 with dMyc and Ras
V12
 causes ER stress 
Using TEM this project reports that when compared with control preparations, nuclei and 
polytene chromosomes of salivary gland cells from NOS2 expressing appeared much smaller, 
but retained their structure (Fig. 3.4.). Interestingly, the secretory vesicles were not visible. 
When co-expression of NOS2 and oncogenes, dMyc and Ras
V12 
separately was conducted, 
the results show that the ER was affected by the combination of each oncogene with NOS2. 
ER structures were not clearly visible suggesting that this co-expression can induce ER stress 
or inhibit development of ER (Fig. 3.7. and Fig. 3.8.). Peroxynitrite can be formed when NO 
reacts with superoxide (ROS) and has been demonstrated to induce ER stress (Dickhout et 
al., 2005). 
Given that NO is overexpressed here via NOS2 and is therefore available in significant 
quantities, this project also reports that each oncogene has the potential to produce 
superoxide. Oncogenic Ras has been shown to produce superoxide in transformed fibroblasts 
(Mitsushita et al., 2004) and H-Ras
V12
 produces ROS via a BLT-Nox-1 linked cascade (Choi 
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et al., 2008). Since transformation of Ras can be inhibited via the action of antioxidants (Irani 
et al., 1997), ROS production facilitates this process.  
c-Myc can also induce the production of ROS, which is demonstrated in human fibroblasts 
(Vafa et al., 2002). Many studies highlight the functional similarities between c-Myc and 
dMyc (Gallant et al., 1996; Trump et al., 2001; Orian et al, 2003). Therefore, dMyc is 
suggested here to act in a similar manner to c-Myc in order to produce ROS.  
These studies suggest that the combination of overexpressing NOS2 and each of the 
oncogenes might produce NO and ROS, respectively, in order to induce ER stress via 
peroxynitrite production. 
  
 6.3. dFOXO
25
/dFOXO
25
 is the strongest loss of function allele of the dFOXO gene 
NO has been previously demonstrated to signal through wild type dFOXO in order to inhibit 
growth in the nuclei of the salivary glands (Scott, 2009). Here it is demonstrated that the level 
of suppression of the NO-induced growth phenotype is dependent on the dFOXO allele used 
and, therefore, presumably on the level of dFOXO activity. Expression of NOS2 in a 
dFOXO
25
 homozygous background (a null allele) produced similar salivary gland nuclei sizes 
(Axiophot) and ultrastructure (TEM) compared to the wild type. Additionally, NOS2- 
expressing animals that were trans-heterozygous for dFOXO
25
  had larger nuclei and more 
normal ultrastructural components when compared with other combinations of dFOXO 
alleles. 
The results show that the dFOXO
25 
homozygotes gave the most suppression of NOS2-
induced phenotypes when compared with the other allelic combinations, since growth 
inhibition via NOS2 was greatly reduced. Jünger et al. (2003) suggested that the different 
strengths of mutation are a result of variations in the position of the stop codons generated by 
the point mutations for dFOXO
21 
and dFOXO
25 
(Fig.4.1.).  
Interestingly, the results show that dFOXO
BG01018
 gave more suppression than the dFOXO
21
 
null allele, which is in contrast to Dionne et al. (2006), which describes dFOXO
BG01018
 as a 
mild mutation (in terms of life span alteration) in comparison to the other two null alleles. 
The dFOXO
BG01018
 mutation is generated by a transposon insertion that acts upstream of the 
dFOXO transcriptional start site, generating a loss of dFOXO function that this present study 
shows is more severe in respect to growth control than dFOXO
21
, but less severe than 
dFOXO
25
. Although Dionne et al. (2006) analysed the effect of dFOXO mutations in terms of 
lifespan (upon exposure to M. marinum) rather than nuclei sizes, the study is similarly 
comparing the effects of the three dFOXO alleles in terms of strength.  
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6.4. Myc, dFOXO and NOS2 induce mitochondrial biogenesis in Drosophila salivary 
glands 
When analysing mitoYFP expression with the oncogenes, and NOS2 and dFOXO, it was 
demonstrated that Ras
V12
 did not act to increase mitochondrial biogenesis when compared 
with the control line. However, overexpression of Myc, dFOXO and NOS2 increased 
mitochondrial biogenesis. 
Ectopic expression of Myc can increase mitochondrial biogenesis in rat P493-6 cells and Myc 
null mutants also show decreased mitochondrial biogenesis (Li et al., 2005). This study 
supports the results demonstrated here. 
Nisoli et al. (2003) showed that eNOS can act to increase mitochondrial biogenesis, but there 
is no evidence to suggest that the isoform used here, NOS2, can also induce this. However, 
the NO donor SNAP has been shown to increase mitochondrial biogenesis in many cells in 
cGMP-dependent activation of PGC-1, which is known to induce mitochondrial biogenesis 
(Nisoli et al., 2003). 
The mammalian homologue of PGC-1, Spargel was demonstrated to be inhibited by dFOXO 
which increases mitochondrial biogenesis (Gersham et al., 2007). Tiefenbock et al. (2010) 
suggested that although these two homologues are both involved in mitochondrial biogenesis 
in mammals and Drosophila, they exhibit opposite effects regarding regulation of this 
biogenesis.  
When investigating the combination of GolgiYFP with these four growth regulators co-
expressed separately, the results did not show any change of GolgiYFP expression when 
compared with wild type controls. This suggests that these growth regulators have no effect 
on Golgi expression which is supported by a lack of evidence for this in the available 
literature. 
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6.5. Future Work 
 
Additional experiments can be conducted in order to confirm that the dFOXO
25
 null allele 
gives the most complete suppression when compared with dFOXO
21
 and dFOXO
BG01018
. 
Previous work has shown that dFOXO acts a crucial mediator of NO signalling  
In order to confirm the results that show increased mitochondria expression in cells that 
overexpressed dFOXO, Myc and NOS2, this thesis suggests that future experiments could 
generate RNAi lines for the three growth regulators and analyse mitochondrial expression in 
the salivary glands using mitoYFP. Expression of mitochondria could be analysed and 
compared with the results seen here. If mitochondria expression is decreased, then that result 
would support the roles of these growth regulators in mitochondrial biogenesis. 
 
This present study did not investigate mitoYFP expression in dFOXO mutants in the presence 
and absence of NOS2 expression. Further research could be conducted in the future to 
explore the effects that dFOXO mutations would have on mitoYFP expression and NO 
signalling.  
 
Given that this study suggests a possible involvement of NO-induced peroxynitrite generation 
in ER stress formation seen in the salivary glands, future research could also compare the 
levels of peroxynitrite in animals expressing NOS2, and Myc or Ras
V12
 with levels observed 
in wild type animals. Results from such studies could help quantify the effect of NOS2 and 
these oncogenes on peroxynitrite production.  
 
Another important observation in this study was the inhibitory effect of NO on secretory 
vesicle expression. There was a positive correlation between the magnitude of this effect and 
the deleterious strength of each dFOXO allele combination. In order to supplement these 
results, research could be conducted that overexpress dFOXO instead of using dFOXO 
mutants. Indeed, this was attempted in this present study. However, overexpression of 
dFOXO yielded very small salivary glands that were difficult to maintain intact during the 
TEM preparations. As a result, the results were not included. Future experimental designs 
could attempt to accommodate this limitation and preserve the glands for visualisation.  
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Appendices 
 
 
Section I. Drosophila Fly Stocks Used 
 
Table 1. Bloomington Stock order No. http://flystocks.bio.indiana.edu/ 
 
 
 
 
                                                                                         
Table 2. Fly stocks from M.Dionne. 
 
 
 
Stock 
# 
Genotype Comments 
4847 w[1118]; P{w[+mC]=UAS-
Ras85D.V12}TL1 
Expresses  activated Ras 
6979 w[1118]; P{w[+mW.hs]=GawB}C147 GAL4 expressed in larval brain and salivary 
glands 
9575 y[1] w[*]; P{w[+mC]=UAS-foxo.P}2 Expresses wild type dfoxo under UAS 
control 
7193 w[*]; P{w[+mC]=sqh-EYFP-Golgi}3 Ubiquitously-expressed EYFP tagged with 
Golgi targeting sequence 
7194 w[*]; P{w[+mC]=sqh-EYFP-Mito}3 Ubiquitously-expressed EYFP tagged with 
mitochondial targeting sequence 
9575 y[1] w[*]; P{w[+mC]=UAS-foxo.P}2 Expresses wild type dfoxo under UAS 
control 
9674 w[1118]; P{w[+mC]=UAS-dm.Z}132 Expresses wild type dm ( Drosophila myc ) 
under UAS control 
Genotype Chromosome Comments and Reference 
y w; ; FRT82[y+] foxo[21] / TM3, Sb[1] Ser[1] 3 
foxo nulls, as reported by 
Junger et al in J Biol 2(3): 20 
w[1118]; ; FRT82[y+] foxo[25] / TM6c, Sb[1] 3 
foxo nulls, as reported by 
Junger et al in J Biol 2(3): 20 
w[1118]; ; foxo[BG01018] 3 
foxo hypomorph  found  
(Dionne et al Curr Biol 
16(20): 1977) 
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Table 3. Fly stocks from other sources. 
 
 
 
 
Section II. Salivary Gland Nuclei Measurements discussed in Chapter 4 
(Raw Data) 
The following is a table of the raw data for measurements of salivary gland nuclei visualised by DAPI staining. 
All glands were obtained from female third instar Drosophila larvae. All measurements were recorded at 40x  
magnification. The genotypes are identified below. (A-G) 
 
 
A B C D E F G 
 
23.93 7.97 23.12 14.21 16.6 20.36 15.2 
 
23.11 8.55 20.61 16.41 15.89 18.43 13.32 
 
25.54 12.2 20.3 15.76 17.79 19.32 13.96 
 
21.58 9.65 22.8 12.45 17.32 16.56 12.99 
 
24.61 9.27 19.12 14.64 16.98 17.73 13.22 
 
22.34 10.24 21.9 14.98 15.65 20.53 13.88 
 
25.94 9.96 19.45 13.76 19.9 17.43 13.31 
 
23.76 8.99 23.41 15.67 16.53 16.9 12.96 
 
23.76 7.16 24.45 15.2 18.31 17.32 16.28 
 
21.34 9.99 20.94 11.98 20.4 20.52 14.4 
 
24.14 11.32 20.23 14.82 15.42 20.32 15.31 
 
22.36 8.51 21.18 15.32 17.21 18.92 14.18 
 
20.28 10.31 24.9 14.43 16.93 19.93 14.13 
 
22.97 7.78 20.23 15.35 16.65 21.82 13.97 
 
25.21 10.52 20.31 14.21 15.89 18.24 14.65 
 
23.27 11.32 24.15 16.2 16.21 19.89 12.99 
 
21.52 8.93 22.11 15.17 17.31 21.67 13.45 
 
25.87 11.1 22.18 13.77 18.2 18.93 15.52 
 
22.59 13.14 22.5 16.46 19.5 18.52 14.23 
 
22.34 11.8 23.86 14.9 15.95 19.98 14.54 
 
21.95 10.65 18.89 14.29 16.8 21.83 13.33 
 
22.51 8.58 21.32 13.98 17.31 22.46 13.21 
 
20.31 11.58 22.42 13.41 17.23 23.1 12.93 
 
26.63 10.6 23.56 15.76 18.24 19.98 12.22 
 
24.14 10.12 20.49 14.68 18.93 19.58 12.21 
 
24.3 10.88 18.93 13.69 20.43 22.34 15.98 
 
23.18 8.59 25.21 12.79 17.83 22.54 15.54 
Genotype Chromosome Comments and Reference 
UAS-NOS2 1 Expresses the constitutively active  mouse NOS2 protein under UAS control ( This lab) 
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23.98 9.97 18.8 12.88 16.71 20.73 12.24 
 
28.9 10.23 21.1 15.22 15.93 18.77 12.98 
 
27.2 9.74 21.52 13.65 16.87 18.68 15.32 
 
24.51 12.29 19.9 14.13 18.36 19.95 13.37 
 
23.8 7.65 24.3 12.03 17.44 20.38 13.98 
 
25.82 10.3 23.73 14.66 13.95 20.94 12.21 
 
27.1 7.33 21.32 14.27 17.62 19.9 11.31 
 
25.2 12.94 23.89 16.2 13.98 18.84 14.36 
 
23.24 11.15 18.93 13.58 19.21 16.5 13.43 
 
22.37 9.21 20.8 12.63 17.31 19.94 15.36 
 
22.8 11.3 23.86 13.99 18.11 17.93 13.57 
 
25.98 6.77 16.94 14.52 16.84 20.5 14.71 
 
22.51 10.19 19.8 15.87 17.54 18.69 14.46 
 
21.4 10.73 19.54 15.24 16.31 19.91 12.87 
 
22.56 7.88 24.25 12.98 16.99 19.94 12.65 
 
24.45 7.41 24.67 13.76 18.41 19.8 15.32 
 
24.65 7.9 23.51 15.63 17.76 16.9 12.7 
 
22.1 10.55 23.87 13.76 15.31 18.93 14.45 
 
25.12 8.92 22.31 14.17 15.95 19.9 14.21 
 
22.96 9.95 25.2 14.74 16.41 19.68 12.87 
 
25.51 7.65 24.21 15.66 13.86 19.62 11.97 
 
21.56 10.9 20.49 15.11 19.98 17.91 12.31 
 
23.43 9.84 23.3 16.36 19.21 16.93 16.67 
 
25.43 13.47 25.2 12.89 17.79 20.7 12.67 
 
22.4 10.2 22.68 15.12 19.76 19.93 13.34 
 
27.93 10.16 23.63 16.29 17.98 20.73 14.51 
 
23.19 8.79 18.92 15.44 16.26 20.4 13.83 
 
23.41 9.44 22.5 14.87 20.76 21.38 13.21 
 
23.76 10.19 21.81 15.74 14.98 18.74 12.19 
 
27.2 9.5 19.89 14.31 15.21 16.96 14.32 
 
20.68 9.34 19.94 16.47 19.45 19.12 13.21 
 
21.7 10.14 24.2 14.55 18.6 19.32 14.42 
 
21.62 6.65 24.23 15.94 15.23 20.27 14.2 
 
26.7 9.11 22.1 16.24 17.44 20.23 11.98 
 
22.16 11.23 21.96 14.51 14.1 18.9 12.96 
 
22.4 12.2 23.94 13.69 18.81 19.95 14.32 
 
25.59 10.11 22.83 15.31 17.96 19.25 14.43 
 
23.4 12.28 21.1 15.88 18.46 20.93 14.23 
 
22.51 12.7 24.5 14.61 17.25 19.96 15.2 
 
22.61 10.8 20.59 16.72 16.31 21.6 13.21 
 
24.83 10.45 20.84 14.55 19.41 17.43 12.21 
 
21.57 10.2 22.83 12.89 17.11 17.98 13.98 
 
25.13 7.57 18.41 17.12 14.92 21.9 16.7 
 
27.2 10.57 24.56 15.3 18.97 23.45 13.98 
 
21.44 9.4 21.45 15.74 15.65 16.96 12.25 
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21.59 10.14 22.67 17.54 18.21 18.15 12.31 
 
22.89 11.19 23.3 14.39 16.41 21.43 12.97 
 
25.41 11.1 21.4 16.17 13.22 17.4 13.66 
 
21.76 10.37 23.23 15.41 16.72 19.58 13.98 
 
23.6 7.2 21.67 16.44 15.22 19.7 12.66 
 
23.34 10.3 21.24 13.8 14.21 19.9 15.42 
 
22.67 10.29 20.4 14.98 15.93 18.32 13.52 
 
23.45 8.59 22.38 15.39 15.26 18.45 12.9 
 
21.8 12.34 21.28 17.2 17.12 20.34 16.53 
 
22.51 10.41 24.2 14.9 16.62 17.83 15.21 
 
22.9 9.63 19.32 15.3 16.63 16.93 15.32 
 
23.2 7.65 20.34 16.54 17.98 18.8 14.21 
 
22.2 7.79 19.43 14.15 15.85 17.1 12.98 
 
25.32 9.36 20.32 17.1 18.32 19.43 12.09 
 
24.88 10.81 26.64 15.1 17.54 19.93 13.3 
 
24.5 11.19 21.2 13.35 16.98 18.66 12.02 
 
24.61 8.8 24.3 14.98 15.98 19.93 14.76 
 
25.31 10.1 22.34 16.58 16.79 18.45 16.93 
 
22.8 8.83 24.32 14.31 17.89 19.93 15.95 
 
19.93 6.99 23.1 16.69 15.89 20.8 12.72 
 
22.56 10.31 21.2 16.22 16.6 16.9 15.54 
 
24.5 12.6 25.25 13.99 18.21 18.43 15.74 
 
25.61 9.16 24.45 15.43 17.31 20.72 12.74 
 
20.93 10.44 23.53 14.51 19.54 17.25 13.94 
 
22.32 9.63 21.38 17.55 16.21 18.63 12.56 
 
23.53 9.25 20.63 15.41 16.51 19.63 13.52 
 
24.9 10.79 24.21 14.71 17.98 20.23 15.6 
 
26.2 8.54 23.13 16.98 19.2 18.96 14.43 
 
20.65 8.96 23.43 16.41 18.98 22.58 14.33 
 
24.2 7.61 23.51 13.89 17.71 18.88 13.37 
 
24.97 10.95 22.47 15.78 16.21 18.7 14.55 
 
21.73 6.65 22.53 14.42 18.21 19.93 13.32 
 
22.41 9.95 20.72 14.21 15.96 20.79 15.21 
 
21.88 10.87 19.51 15.76 18.21 20.6 16.98 
 
22.27 10.1 25.51 14.6 19.9 19.42 15.32 
 
23.49 8.62 25.21 15.98 20.96 19.97 12.99 
 
24.12 13.14 22.5 14.67 15.62 21.85 12.94 
 
24.43 11.12 25.51 13.9 17.31 20.34 15.19 
 
23.61 7.21 21.62 14.87 16.32 19.89 14.66 
 
22.7 11.34 21.52 16.21 14.44 21.29 12.39 
 
25.71 12.95 27.14 15.91 15.9 21.8 12.43 
 
25.51 12.3 21.6 13.86 16.31 17.73 12.95 
 
23.87 9.95 23.41 15.46 17.5 18.59 13.21 
 
25.51 8.58 21.23 14.6 18.96 19.93 14.32 
 
24.7 13.1 22.8 16.23 16.89 20.8 13.41 
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25.29 12.23 22.61 15.92 19.92 21.7 14.2 
 
23.66 10.62 26.32 15.27 18.32 19.53 16.32 
 
24.33 10.54 19.3 15.43 16.32 22.29 12.62 
 
22.41 8.67 20.59 16.52 17.31 18.87 14.33 
 
23.9 10.52 22.98 14.59 14.71 18.67 14.21 
 
24.23 10.43 24.44 15.21 17.65 20.52 11.19 
 
25.18 11.28 21.9 16.28 17.14 21.16 13.98 
 
26.12 8.99 22.83 13.63 15.21 20.59 11.49 
 
22.44 7.63 25.21 14.34 16.21 20.39 15.76 
 
23.49 10.26 22.73 16.45 14.92 19.44 14.48 
 
23.76 10.86 21.16 15.92 15.31 17.93 12.97 
 
28.23 10.1 22.41 15.69 16.41 21.24 12.34 
 
22.41 12.5 23.73 16.41 15.39 19.94 12.2 
 
22.1 9.93 21.41 13.98 20.95 21.4 14.21 
 
27.32 12.9 22.6 13.62 16.21 20.36 13.21 
 
26.2 10.98 23.41 11.21 15.61 18.98 11.21 
 
27.9 10.81 18.4 16.13 16.95 19.9 14.11 
 
23.33 11.98 22.73 15.96 16.93 20.58 16.15 
 
24.41 13.4 22.61 15.31 15.42 17.66 12.95 
 
23.77 9.46 21.85 13.98 20.21 20.47 11.34 
 
24.62 10.93 26.77 15.65 21.4 20.13 15.6 
 
22.88 7.56 20.21 16.9 17.43 19.63 10.98 
 
22.26 8.33 25.4 15.97 23.4 18.62 13.85 
 
24.94 10.21 21.94 15.47 14.41 19.96 12.21 
 
26.87 8.81 20.83 16.8 17.65 20.55 16.9 
 
26.41 11.2 21.7 16.89 19.66 19.1 16.38 
 
22.41 11.32 21.43 14.95 14.42 17.71 11.34 
 
26.33 7.53 23.13 16.55 17.9 19.47 14.39 
 
25.57 9.98 23.62 14.54 18.51 20.13 11.32 
 
26.3 8.9 21.34 14.64 17.97 18.98 15.21 
 
25.16 10.28 21.62 15.74 16.87 20.59 13.24 
 
24.39 11.66 20.55 15.36 18.3 20.23 13.21 
Average = 23.86 10.02 22.27 15.05 17.21 19.63 13.81 
Standard deviation = 1.804617 1.573675 1.942176 1.196942 1.707855 1.442174 1.359224 
 
A: Control Genotype (c147-GAL4/+) 
B: Overexpression of NOS2(UAS-NOS2/+; c147-GAL4/+) 
C: UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
25
 
D: UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
BG01018
 
E:  UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
BG01018
/ dFOXO
BG01018
 
 F: UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
25
/ dFOXO
21
 
G: UAS-NOS2,UAS-GFP/+;c147/+;dFOXO
21
/ dFOXO
BG01018 
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III. Raw Data from Statistical Analysis of Salivary Gland Nuclei measurements 
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One-way ANOVA: DATA versus GENES 
 
 
 
Source    DF        SS       MS        F      P 
Factor     6  21347.17  3557.86  1394.13  0.000 
Error   1036   2643.90     2.55 
Total   1042  23991.07 
 
S = 1.598   R-Sq = 88.98%   R-Sq(adj) = 88.92% 
 
 
 
 
Level                       N    Mean  StDev 
Control Genotype          149  23.860  1.805 
NOS2                      149  10.020  1.579 
NOS2 dFOXO25/dFOXO25      149  22.267  1.945 
NOS2 dFOXO25/dFOXO21      149  15.052  1.201 
NOS2 dFOXO BG01018/dFOXO  149  17.212  1.714 
NOS2 dFOXO25/ dFOXOBG010  149  19.625  1.447 
NOS2 dFOXO21/dFOXO BG010  149  13.809  1.364 
 
                          Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level                     ------+---------+---------+---------+--- 
Control Genotype                                             (* 
NOS2                      (*) 
NOS2 dFOXO25/dFOXO25                                     (* 
NOS2 dFOXO25/dFOXO21                   (* 
NOS2 dFOXO BG01018/dFOXO                    (*) 
NOS2 dFOXO25/ dFOXOBG010                          (*) 
NOS2 dFOXO21/dFOXO BG010            (* 
                          ------+---------+---------+---------+--- 
                             12.0      16.0      20.0      24.0 
 
Pooled StDev = 1.598 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons 
 
Individual confidence level = 99.67% 
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Control Genotype subtracted from: 
 
                            Lower   Center    Upper 
NOS2                      -14.385  -13.839  -13.294 
NOS2 dFOXO25/dFOXO25       -2.139   -1.593   -1.047 
NOS2 dFOXO25/dFOXO21       -9.354   -8.808   -8.262 
NOS2 dFOXO BG01018/dFOXO   -7.193   -6.647   -6.102 
NOS2 dFOXO25/ dFOXOBG010   -4.780   -4.235   -3.689 
NOS2 dFOXO21/dFOXO BG010  -10.596  -10.051   -9.505 
 
                             -+---------+---------+---------+-------- 
NOS2                         (*) 
NOS2 dFOXO25/dFOXO25                           (*) 
NOS2 dFOXO25/dFOXO21                 *) 
NOS2 dFOXO BG01018/dFOXO                (* 
NOS2 dFOXO25/ dFOXOBG010                   (*) 
NOS2 dFOXO21/dFOXO BG010           (* 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
 
 
NOS2 subtracted from: 
 
                           Lower  Center   Upper 
NOS2 dFOXO25/dFOXO25      11.701  12.247  12.792 
NOS2 dFOXO25/dFOXO21       4.486   5.031   5.577 
NOS2 dFOXO BG01018/dFOXO   6.646   7.192   7.738 
NOS2 dFOXO25/ dFOXOBG010   9.059   9.605  10.151 
NOS2 dFOXO21/dFOXO BG010   3.243   3.789   4.335 
 
                             -+---------+---------+---------+-------- 
NOS2 dFOXO25/dFOXO25                                               *) 
NOS2 dFOXO25/dFOXO21                                    (*) 
NOS2 dFOXO BG01018/dFOXO                                   (*) 
NOS2 dFOXO25/ dFOXOBG010                                       (*) 
NOS2 dFOXO21/dFOXO BG010                               *) 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
 
 
NOS2 dFOXO25/dFOXO25 subtracted from: 
 
                           Lower  Center   Upper 
NOS2 dFOXO25/dFOXO21      -7.761  -7.215  -6.669 
NOS2 dFOXO BG01018/dFOXO  -5.600  -5.055  -4.509 
NOS2 dFOXO25/ dFOXOBG010  -3.188  -2.642  -2.096 
NOS2 dFOXO21/dFOXO BG010  -9.003  -8.458  -7.912 
 
                             -+---------+---------+---------+-------- 
NOS2 dFOXO25/dFOXO21                   (* 
NOS2 dFOXO BG01018/dFOXO                  (*) 
NOS2 dFOXO25/ dFOXOBG010                     (*) 
NOS2 dFOXO21/dFOXO BG010             (*) 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
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NOS2 dFOXO25/dFOXO21 subtracted from: 
 
                           Lower  Center   Upper 
NOS2 dFOXO BG01018/dFOXO   1.615   2.161   2.706 
NOS2 dFOXO25/ dFOXOBG010   4.028   4.573   5.119 
NOS2 dFOXO21/dFOXO BG010  -1.788  -1.243  -0.697 
 
                             -+---------+---------+---------+-------- 
 
NOS2 dFOXO BG01018/dFOXO                            (*) 
NOS2 dFOXO25/ dFOXOBG010                                (* 
NOS2 dFOXO21/dFOXO BG010                       (*) 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
 
 
NOS2 dFOXO BG01018/dFOXO BG0 subtracted from: 
 
                           Lower  Center   Upper 
NOS2 dFOXO25/ dFOXOBG010   1.867   2.413   2.959 
NOS2 dFOXO21/dFOXO BG010  -3.949  -3.403  -2.857 
 
                             -+---------+---------+---------+-------- 
NOS2 dFOXO25/ dFOXOBG010                             *) 
NOS2 dFOXO21/dFOXO BG010                    (*) 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
 
 
NOS2 dFOXO25/ dFOXOBG01018 subtracted from: 
 
                           Lower  Center   Upper 
NOS2 dFOXO21/dFOXO BG010  -6.362  -5.816  -5.270 
 
                             -+---------+---------+---------+-------- 
NOS2 dFOXO21/dFOXO BG010                 (* 
                             -+---------+---------+---------+-------- 
                          -14.0      -7.0       0.0       7.0 
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